Therapeutic use of crispr type v system
By combining the Cas12a protein with CRISPR guide RNA and delivering it to somatic cells using lipid nanoparticles, the insertion, deletion, or modification of specific gene target sequences can be achieved. This solves the problems of precision and efficiency in gene editing in existing technologies and enables effective treatment of diseases with abnormal gene expression.
Patent Information
- Application Number
- CN202380029750.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-18
- Filing Date
- 2023-04-12
- Publication Date
- 2024-11-15
AI Technical Summary
Existing technologies struggle to effectively utilize the CRISPR-Cas system for genome editing to treat diseases caused by abnormal gene expression, particularly due to issues of precision and efficiency both in vivo and in vitro.
By using the combination of Cas12a protein and CRISPR guide RNA, the gene is delivered to somatic cells via lipid nanoparticles to insert, delete, or modify specific gene target sequences. Repair is then performed using HDR or NHEJ to achieve the purpose of gene editing.
It enables precise gene editing both in vivo and in vitro, effectively treating diseases caused by abnormal gene expression and improving the precision and efficiency of treatment.
Smart Images

Figure BDA0005056039140000181 
Figure BDA0005056039140000191 
Figure BDA0005056039140000211
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application Serial No. 63 / 330,695 filed on April 13, 2022 and U.S. Provisional Application Serial No. 63 / 332,173 filed on April 18, 2022, all of which are incorporated herein by reference.
[0003] Statement Regarding Federally Funded Research
[0004] not applicable. Technical Field
[0005] The present disclosure relates generally to the field of cell therapy utilizing cells modified with the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system, more specifically the CRISPR-Cas12 system. Background Art
[0006] Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-related (Cas) protein systems are present in the genomes of many prokaryotes and provide adaptive immunity against viruses. The latest descriptions and classifications of various CRISPR-Cas systems in their natural hosts (1 type I; 2 types II and V), RNA targeting (2 types VI), and DNA and RNA combined targeting (1 type III) can be found in Makarova et al. ("Natural Review: Microbiology (Nat. Rev. Microbiol.) ", 2020, 18: 67-83). Particularly interesting is the V-type system, which includes different subtypes, for example, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK and VU. VA subtype encodes Cas12a protein (formerly known as Cpf1). Cas12a has a RuvC-like nuclease domain homologous to the corresponding domain of Cas9 but lacks an HNH nuclease domain.
[0007] Type V systems have been found in several bacteria, including Parcubacteriabacterium GWC2011_GWC2_44_17 (PbCpf1), Lachnospiraceae bacterium MC2017 (Lb3 Cpf1), Butyrivibrio proteoclasticus (BpCpf1), Peregrinibacteria bacterium GW2011_GWA_33_10 (PeCpf1), Acidaminococcus sp. BV3L6 (AsCpf1), Porphyromonas spp. macacae)(PmCpf1), Lachnospiraceae ND2006(LbCpf1), Porphyromonascrevioricanis(PcCpf1), Prevotella disiens(PdCpf1), Moraxella bovoculi 237(MbCpf1), Smithella sp. SC_K08D17(SsCpf1), Leptospira inadai(LiCpf1), Lachnospiraceae MA2020(Lb2Cpf1), Francisella novicida U112(FnCpf1), Candidatus methanoplasma termitum) (CMtCpf1) and Eubacterium eligens (EeCpf1).
[0008] CRISPR-Cas system provides a powerful tool for performing fixed-point genome editing by deletion, insertion, mutation or replacement of specific nucleic acid sequences. The change may be gene-specific or position-specific. Genome editing can use fixed-point nucleases (such as Cas proteins and their homologous polynucleotides) to cut target nucleic acids, thereby generating sites for changes. In some cases, cutting can introduce double-strand breaks (DSBs) in target DNA sequences. DSBs can be repaired, for example, by non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ) or homology-directed repair (HDR). HDR relies on the presence of a template to repair. In some examples of this genome editing, donor polynucleotides or parts thereof can be inserted into the break. Summary of the invention
[0009] This genome editing approach utilizing type V CRISPR-Cas proteins, such as Cas12a, in combination with CRISPR hybrid RNA-DNA guides (chRDNA) is particularly useful for generating genetically modified cells for therapeutic applications.
[0010] In some embodiments, the present invention is a method for treating a disease or condition characterized by abnormal expression of a gene, the method comprising introducing the following into a somatic cell of a patient suffering from a disease or condition: (a) a first nucleoprotein complex, the first nucleoprotein complex comprising a Cas12a protein and a first CRISPR guide molecule, the first CRISPR guide molecule having a targeting region capable of binding to a first target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; and (b) a donor polynucleotide comprising a coding sequence of a gene target abnormally expressed in an individual suffering from the disease or condition; wherein the cleavage performed by the Cas12a protein causes the coding sequence to be inserted into the genome of the somatic cell, and wherein the introduction is performed by contacting the somatic cell with a lipid nanoparticle comprising the first nucleoprotein complex and the donor polynucleotide, and wherein the gene target is selected from Table 3. In some embodiments, in the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide. In some embodiments, the method further comprises introducing into the somatic cell a second nucleoprotein complex comprising a Cas12a protein and a second CRISPR guide molecule, wherein the second CRISPR guide molecule has a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving a second target nucleic acid; wherein the coding sequence is inserted between the first target nucleic acid cleaved by the Cas12a protein and the cleavage site in the second target nucleic acid. In some embodiments, the second CRISPR guide molecule comprises at least one deoxyribonucleotide.
[0011] In some embodiments, the inserting of the coding sequence into the genome of the somatic cell causes the expression of the gene in the somatic cell to increase. In some embodiments, the lipid nanoparticle comprises one or more cationic lipids, wherein the pK of the lipid or a combination of two or more lipids is aBetween 6.1 and 6.7. In some embodiments, the lipid nanoparticles include neutral lipids. In some embodiments, the lipid nanoparticles include sterols. In some embodiments, the lipid nanoparticles include one or more lipids selected from the group consisting of: DSPC, DPPC, POPC, DOPE, SM, PEG-DMA, PEG-DMG, DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE, GL67A-DOPE-DMPE-PEG, 98N12-5, C12-200, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, 7C1, PEG-CerC14 and PEG-CerC20.
[0012] In some embodiments, the introduction into the somatic cell is performed ex vivo. In some embodiments, the introduction into the somatic cell is performed by systemic intravenous administration, administration into the portal vein, or by intraocular administration.
[0013] In some embodiments, the present invention is a therapeutic composition for treating a disease or condition characterized by abnormal expression of a gene, the composition comprising: (a) a first nucleoprotein complex, the first nucleoprotein complex comprising a Cas12a protein and a first CRISPR guide molecule, the first CRISPR guide molecule having a targeting region capable of binding to a first target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; and (b) a donor polynucleotide comprising a coding sequence of a gene target abnormally expressed in an individual suffering from the disease or condition; wherein the first nucleoprotein complex and the donor polynucleotide are present in lipid nanoparticles, and wherein the gene target is selected from Table 3. In some embodiments, in the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide.
[0014] In some embodiments, the composition further includes a second nucleoprotein complex, the second nucleoprotein complex includes a Cas12a protein and a second CRISPR guide molecule, the second CRISPR guide molecule having a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving a second target nucleic acid. In some embodiments of the composition, the second CRISPR guide molecule includes at least one deoxyribonucleotide. In some embodiments of the composition, the lipid nanoparticle includes one or more cationic lipids, wherein the pK of the lipid or a combination of two or more lipids is greater than or equal to 1. a Between 6.1 and 6.7. In some embodiments of the composition, the lipid nanoparticles include neutral lipids. In some embodiments of the composition, the lipid nanoparticles include sterols. In some embodiments of the composition, the lipid nanoparticles include one or more lipids selected from the group consisting of: DSPC, DPPC, POPC, DOPE, SM, PEG-DMA, PEG-DMG, DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE, GL67A-DOPE-DMPE-PEG, 98N12-5, C12-200, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, 7C1, PEG-CerC14 and PEG-CerC20. In some embodiments, the composition further includes a pharmaceutically acceptable carrier.
[0015] In some embodiments, the present invention is a method for treating a disease or condition characterized by abnormal expression of a gene with a genetically modified differentiated induced pluripotent stem cell (iPSC), the method comprising: (1) introducing the following into iPSC: a first nucleoprotein complex, the first nucleoprotein complex comprising a Cas12a protein and a first CRISPR guide molecule, the first CRISPR guide molecule having a targeting region capable of binding to a first target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; wherein the cleavage performed by the Cas12a protein causes modification of a gene target selected from Table 4 or Table 5; (2) differentiating the iPSC into a cell type affected by the disease or condition in an individual suffering from the disease or condition; and (3) administering differentiated iPSC to a patient affected by the disease or condition. In some embodiments, in the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide.
[0016] In some embodiments, the method further includes introducing a second nucleoprotein complex including a Cas12a protein and a second CRISPR guide molecule into the iPSC, the second CRISPR guide molecule having a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein capable of cleaving a second target nucleic acid; wherein the coding sequence is inserted between the cleavage site in the first target nucleic acid cleaved by the Cas12a protein and the second target nucleic acid. In some embodiments of the method, the second CRISPR guide molecule includes at least one deoxyribonucleotide. In some embodiments, the method further includes introducing a donor polynucleotide into the iPSC, the donor polynucleotide including a coding sequence of a gene target selected from Table 4. In some embodiments of the method, the cleavage performed with the Cas12a protein causes the coding sequence to be inserted into the genome of the iPSC. In some embodiments of the method, the insertion of the coding sequence into the genome of the iPSC causes the expression of the gene in the iPSC to increase. In some embodiments of the method, the cutting performed with the Cas12a protein causes the destruction of the coding sequence of the gene target listed in Table 5 in the genome of the iPSC. In some embodiments of the method, the destruction in the genome of the iPSC causes the expression of the gene in the iPSC to be reduced. In some embodiments of the method, the iPSC is produced by reprogramming somatic cells. In some embodiments of the method, the reprogramming is performed by inducing the expression of one or more genes in the somatic cells. In some embodiments of the method, the reprogramming is performed by inducing gene expression, which is performed by introducing mRNA into the somatic cells. In some embodiments of the reprogramming, the one or more genes are selected from Oct4, Sox2, Klf4, c-Myc, NANOG, Sox1, Sox3, Sox15, Sox18, Klf1, Klf2, Klf5, NR5A2, c-Myc, l-Myc, n-Myc, Rem2, Tert, LIN28 and Wnt. In some embodiments of the reprogramming, the one or more genes consist of a combination of Oct4, Sox2, Klf4 and c-Myc. In some embodiments of the reprogramming, the one or more genes consist of a combination of Oct4, Sox2 and NANOG.In some embodiments of the method, the reprogramming further comprises contacting the iPSC with one or more of: a MEK inhibitor, a DNA methyltransferase inhibitor, a histone deacetylase (HDAC) inhibitor, valproic acid, 5'-azacytidine, dexamethasone, suberoylanilide hydroxamic acid (SAHA), vitamin C and trichostatin (TSA), suberoylanilide hydroxamic acid (SAHA (e.g., MK0683, vorinostat) and other hydroxamic acids), BML-210, Depudecin (e.g., (-)-Depudecin), HC toxin, Nullscript (4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxybutyramide), phenylbutyrate (e.g., sodium phenylbutyrate), and valproic acid ((VP A) and other short-chain fatty acids), Scriptaid, Suramin Sodium, Trichostatin A (TSA), APHA Compound 8, Apicidin, Sodium Butyrate, Pivanex, AN-9, Trapoxin B, Chlamydocin, Depsipeptide (also known as FR901228 or FK228), Benzamides (e.g., CI-994 (e.g., N-acetyl pyridamole), dinaline) and MS-27-275), MGCD0103, NVP-LAQ-824, CBHA (m-carboxycinnamic acid dihydroxamic acid), JNJ16241199, Tubacin, A-161906, proxamide, oxamflatin, 3-C1-UCHA (e.g., 6-(3-chlorophenylureido)hexanehydroxamic acid), AOE (2-amino-8-oxo-9,10-epoxydecanoic acid), CHAP31 and CHAP50. In some embodiments of the method, the iPSC is differentiated into neurons. In some embodiments of the method, the iPSCs are differentiated into neurons by incubating the iPSCs in the presence of one or more of the following: a GSK-3 inhibitor, a TGF-β receptor or a TGF-β inhibitor, an ALK inhibitor, dorsomorphin, Compound E, FGF, EGF, all-trans retinoic acid, Sonic Hedgehog protein, purmorphamine, SAG dihydrochloride, CNTF, and GDNF.In some embodiments of the method, the differentiation of iPSCs into neurons is assessed by measuring the expression of one or more of Sox1, Pax6, Nestin, HB9, MAP2, neurofilaments, Tuj1, and Olig2 after the differentiation process. In some embodiments of the method, the differentiation of iPSCs into neurons is assessed by measuring the electrical activity of the cells after the differentiation process.
[0017] In some embodiments of the method, wherein the iPSC is differentiated into muscle cells. In some embodiments of the method, the iPSC is differentiated into muscle cells by incubating the iPSC in the presence of one or more of a GSK-3 inhibitor and a Wnt-dependent phosphorylation blocker. In some embodiments of the method, the differentiation of the iPSC into muscle cells is assessed by measuring the expression of one or more of TBX5, TNNT2, MYH6, and MYL7 after the differentiation process.
[0018] In some embodiments, the present invention is a composition for treating a disease or condition characterized by abnormal expression of a gene with a genetically modified differentiated induced pluripotent stem cell (iPSC), the composition comprising iPSC, the iPSC comprising: a first nucleoprotein complex, the first nucleoprotein complex comprising a Cas12a protein and a first CRISPR guide molecule, the first CRISPR guide molecule having a targeting region capable of binding to a first target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; wherein the cleavage performed by the Cas12a protein causes modification of a gene target selected from Table 4 or Table 5; and the iPSC is capable of differentiating into a cell type affected by the disease or condition in an individual suffering from the disease or condition. In some embodiments of the composition, the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide. In some embodiments, the composition further includes introducing a second nucleoprotein complex including a Cas12a protein and a second CRISPR guide molecule into the iPSC, the second CRISPR guide molecule having a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein capable of cutting a second target nucleic acid; wherein the coding sequence is inserted between the first target nucleic acid cut by the Cas12a protein and the cutting site in the second target nucleic acid. In some embodiments of the composition, the second CRISPR guide molecule includes at least one deoxyribonucleotide. In some embodiments, the composition further includes a donor polynucleotide, which includes a coding sequence of a gene target selected from Table 4. In some embodiments of the composition, the cutting performed with the Cas12a protein causes the coding sequence to be inserted into the genome of the iPSC. In some embodiments of the composition, the insertion of the coding sequence into the genome of the iPSC causes the expression of the gene in the iPSC to increase. In some embodiments of the composition, the cleavage performed with the Cas12a protein causes the destruction of the coding sequence of the gene target listed in Table 5 in the genome of the iPSC. In some embodiments of the composition, the destruction in the genome of the iPSC causes the expression of the gene in the iPSC to be reduced. In some embodiments of the composition, the iPSC is produced by reprogramming somatic cells. In some embodiments of the composition, the reprogramming is performed by inducing the expression of one or more genes in the somatic cells.In some embodiments of the composition, the reprogramming is performed by inducing gene expression, which is performed by introducing mRNA into the somatic cells. In some embodiments of the composition, the one or more genes are selected from Oct4, Sox2, Klf4, c-Myc, NANOG, Sox1, Sox3, Sox15, Sox18, Klf1, Klf2, Klf5, NR5A2, c-Myc, l-Myc, n-Myc, Rem2, Tert, LIN28 and Wnt. In some embodiments of the composition, the one or more genes are composed of a combination of Oct4, Sox2, Klf4 and c-Myc. In some embodiments of the composition, the one or more genes are composed of a combination of Oct4, Sox2 and NANOG. In some embodiments of the composition, wherein the reprogramming further comprises contacting the iPSC with one or more of: a MEK inhibitor, a DNA methyltransferase inhibitor, a histone deacetylase (HDAC) inhibitor, valproic acid, 5'-azacytidine, dexamethasone, suberoylanilide hydroxamic acid (SAHA), vitamin C and trichostatin (TSA), suberoylanilide hydroxamic acid (SAHA (e.g., MK0683, vorinostat) and other hydroxamic acids), BML-210, Depudecin (e.g., (-)-Depudecin), HC toxin, Nullscript (4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxybutyramide), phenylbutyrate (e.g., sodium phenylbutyrate), and valproic acid ((VP A) and other short-chain fatty acids), Scritex, suramin sodium, trichostatin A (TSA), APHA compound 8, aphidicolin, sodium butyrate, pivaloyloxymethylbutyrate (Pivanex, AN-9), Trapoxin B ( B), Chlamydocin, depsipeptide (also known as FR901228 or FK228), benzamides (e.g., CI-994 (e.g., N-acetyldinaline) and MS-27-275), MGCD0103, NVP-LAQ-824, CBHA (m-carboxycinnamic acid dihydroxamic acid), JNJ16241199, tobacin, A-161906, proxamide, oxamflatin, 3-C1-UCHA (e.g., 6-(3-chlorophenylureido)hexanehydroxamic acid), AOE (2-amino-8-oxo-9,10-epoxydecanoic acid), CHAP31 and CHAP50.
[0019] In some embodiments of the composition, the iPSC is differentiated into neurons. In some embodiments of the composition, the iPSC is differentiated into neurons by incubating the iPSC in the presence of one or more of the following: GSK-3 inhibitors, TGF-β receptors or TGF-β inhibitors, ALK inhibitors, doxorubicin, compound E, FGF, EGF, all-trans retinoic acid, sonic hedgehog, purmorphamine, SAG dihydrochloride, CNTF and GDNF. In some embodiments of the composition, the iPSC is differentiated into neurons by measuring the expression of one or more of Sox1, Pax6, nestin, HB9, MAP2, neurofilaments, Tuj1 and Olig2 after the differentiation process. In some embodiments of the composition, the iPSC is differentiated into neurons by measuring the electrical activity of the cells after the differentiation process.
[0020] In some embodiments of the composition, the iPSC is differentiated into muscle cells. In some embodiments of the composition, the iPSC is differentiated into muscle cells by incubating the iPSC in the presence of one or more of a GSK-3 inhibitor and a Wnt-dependent phosphorylation blocker. In some embodiments of the composition, the differentiation of the iPSC into muscle cells is assessed by measuring the expression of one or more of TBX5, TNNT2, MYH6, and MYL7 after the differentiation process.
[0021] In some embodiments, the composition further comprises a pharmaceutically acceptable carrier.
[0022] In some embodiments, the present invention is a method for preparing a genetically modified differentiated induced pluripotent stem cell (iPSC) for treating a disease or condition characterized by abnormal expression of a gene, the method comprising: (1) introducing the following into iPSC: a first nucleoprotein complex, the first nucleoprotein complex comprising a Cas12a protein and a first CRISPR guide molecule, the first CRISPR guide molecule having a targeting region capable of binding to a first target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; wherein the cleavage performed by the Cas12a protein causes modification of a gene target selected from Table 4 or Table 5; (2) differentiating the iPSC into a cell type affected by the disease or condition in an individual suffering from the disease or condition; and (3) administering the differentiated iPSC to a patient affected by the disease or condition. In some embodiments of the method, the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide. In some embodiments, the method further includes introducing a second nucleoprotein complex including a Cas12a protein and a second CRISPR guide molecule into the iPSC, the second CRISPR guide molecule having a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein capable of cleaving a second target nucleic acid; wherein the coding sequence is inserted between the cleavage site in the first target nucleic acid cleaved by the Cas12a protein and the second target nucleic acid. In some embodiments of the method, the second CRISPR guide molecule includes at least one deoxyribonucleotide. In some embodiments, the method further includes introducing a donor polynucleotide into the iPSC, the donor polynucleotide including a coding sequence of a gene target selected from Table 4. In some embodiments of the method, the cleavage performed with the Cas12a protein causes the coding sequence to be inserted into the genome of the iPSC. In some embodiments of the method, the insertion of the coding sequence into the genome of the iPSC causes the expression of the gene in the iPSC to increase. In some embodiments of the method, the cleavage performed with the Cas12a protein causes the destruction of the coding sequence of the gene target listed in Table 5 in the genome of the iPSC. In some embodiments of the method, the destruction in the genome of the iPSC causes the expression of the gene in the iPSC to be reduced. In some embodiments of the method, the iPSC is produced by reprogramming somatic cells. In some embodiments of the method, the reprogramming is performed by inducing the expression of one or more genes in the somatic cells.In some embodiments of the method, the reprogramming is performed by inducing gene expression, which is performed by introducing mRNA into the somatic cells. In some embodiments of the reprogramming, the one or more genes are selected from Oct4, Sox2, Klf4, c-Myc, NANOG, Sox1, Sox3, Sox15, Sox18, Klf1, Klf2, Klf5, NR5A2, c-Myc, l-Myc, n-Myc, Rem2, Tert, LIN28 and Wnt. In some embodiments of the reprogramming, the one or more genes are composed of a combination of Oct4, Sox2, Klf4 and c-Myc. In some embodiments of the reprogramming, the one or more genes are composed of a combination of Oct4, Sox2 and NANOG. In some embodiments of the method, the reprogramming further comprises contacting the iPSC with one or more of: a MEK inhibitor, a DNA methyltransferase inhibitor, a histone deacetylase (HDAC) inhibitor, valproic acid, 5'-azacytidine, dexamethasone, suberoylanilide hydroxamic acid (SAHA), vitamin C and trichostatin (TSA), suberoylanilide hydroxamic acid (SAHA (e.g., MK0683, vorinostat) and other hydroxamic acids), BML-210, Depudecin (e.g., (-)-Depudecin), HC toxin, Nullscript (4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxybutyramide), phenylbutyrate (e.g., sodium phenylbutyrate), and valproic acid ((VP A) and other short-chain fatty acids), Scritex, suramin sodium, trichostatin A (TSA), APHA compound 8, aphidicolin, sodium butyrate, pivaloyloxymethylbutyrate (Pivanex, AN-9), Triproxin B, Chlamydocin, depsipeptide (also known as FR901228 or FK228), benzamides (e.g., CI-994 (e.g., N-acetyl pyridamole) and MS-27-275), MGC D0103, NVP-LAQ-824, CBHA (m-carboxycinnamic acid dihydroxamic acid), JNJ16241199, Tubacin, A-161906, proxamide, oxamflatin, 3-C1-UCHA (e.g., 6-(3-chlorophenylureido)hexanehydroxamic acid), AOE (2-amino-8-oxo-9,10-epoxydecanoic acid), CHAP31 and CHAP50.
[0023] In some embodiments of the method, the iPSC is differentiated into neurons. In some embodiments of the method, the iPSC is differentiated into neurons by incubating the iPSC in the presence of one or more of the following: GSK-3 inhibitors, TGF-β receptors or TGF-β inhibitors, ALK inhibitors, doxorubicin, compound E, FGF, EGF, all-trans retinoic acid, sonic hedgehog, purmorphamine, SAG dihydrochloride, CNTF and GDNF. In some embodiments of the method, the iPSC is differentiated into neurons by measuring the expression of one or more of Sox1, Pax6, nestin, HB9, MAP2, neurofilaments, Tuj1 and Olig2 after the differentiation process. In some embodiments of the method, the iPSC is differentiated into neurons by measuring the electrical activity of the cells after the differentiation process.
[0024] In some embodiments of the method, wherein the iPSC is differentiated into muscle cells. In some embodiments of the method, the iPSC is differentiated into muscle cells by incubating the iPSC in the presence of one or more of a GSK-3 inhibitor and a Wnt-dependent phosphorylation blocker. In some embodiments of the method, the differentiation of the iPSC into muscle cells is assessed by measuring the expression of one or more of TBX5, TNNT2, MYH6, and MYL7 after the differentiation process.
[0025] In some embodiments, the present invention is a method for preparing a transgenic animal for xenotransplantation, the method comprising: (1) introducing the following into the cells of the animal: a first nucleoprotein complex, the first nucleoprotein complex comprising a Cas12a protein and a first CRISPR guide molecule, the first CRISPR guide molecule having a targeting region capable of binding to a first target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; wherein the cleavage performed by the Cas12a protein causes modification of a gene target selected from Table 6; (2) introducing the cell into a foster female animal. In some embodiments of the method, the cell of the animal is an oocyte, an egg, or a fertilized egg. In some embodiments of the method, the cell of the animal is a somatic cell, and the method further comprises, after step (1), transferring the nucleus of the cell to an enucleated egg or a fertilized egg. In some embodiments of the method, the animal is a pig. In some embodiments of the method, in the CRISPR guide molecule, the activation region, the targeting region, or both include at least one deoxyribonucleotide. In some embodiments, the method further includes introducing a second nucleoprotein complex including a Cas12a protein and a second CRISPR guide molecule into the iPSC, the second CRISPR guide molecule having a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein capable of cleaving a second target nucleic acid; wherein the coding sequence is inserted between the first target nucleic acid cleaved by the Cas12a protein and the cleavage site in the second target nucleic acid. In some embodiments of the method, the second CRISPR guide molecule includes at least one deoxyribonucleotide. In some embodiments, the method further comprises introducing a donor polynucleotide into the cell, the donor polynucleotide comprising a coding sequence selected from the following gene targets: A20, HO-1, FAT-1, TNF-α receptor, CD39, hirudin, TFPI, EPCR, TBM, CD46, DAF (CD55), CD59, CR1, CTLA4, CD47, one or more class I HLAs of class I HLA. In some embodiments of the method, the cutting performed with the Cas12a protein causes the coding sequence to be inserted into the genome of the cell. In some embodiments of the method, the insertion of the coding sequence into the genome of the cell causes the expression of the gene in the cell to increase.In some embodiments of the method, the cleavage with the Cas12a protein causes disruption of a coding sequence of a gene target selected from the following in the genome of the cell: GGTA1, b4GalNT2, CMAH, GT (α(1,3)-galactosyltransferase), GHR, one or more class I SLAs of class I SLAs. In some embodiments of the method, the disruption in the genome of the cell causes reduced expression of the gene in the cell.
[0026] In some embodiments, the present invention is a composition for preparing a transgenic animal for xenotransplantation, the composition comprising an animal cell, the animal cell comprising: a first nucleoprotein complex, the first nucleoprotein complex comprising a Cas12a protein and a first CRISPR guide molecule, the first CRISPR guide molecule having a targeting region capable of binding to a first target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; wherein the cleavage performed by the Cas12a protein causes modification of a gene target selected from Table 6. In some embodiments of the composition, the cell of the animal is an oocyte, an egg, or a fertilized egg. In some embodiments of the composition, the cell of the animal is an egg or a fertilized egg produced by transferring the nucleus of a somatic cell into an enucleated egg or a fertilized egg. In some embodiments of the composition, the animal is a pig. In some embodiments of the composition, the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide. In some embodiments, the composition further includes introducing a second nucleoprotein complex including a Cas12a protein and a second CRISPR guide molecule into the iPSC, the second CRISPR guide molecule having a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein capable of cleaving a second target nucleic acid; wherein the coding sequence is inserted between the first target nucleic acid cleaved by the Cas12a protein and the cleavage site in the second target nucleic acid. In some embodiments of the composition, the second CRISPR guide molecule includes at least one deoxyribonucleotide. In some embodiments, the composition further includes a donor polynucleotide, the donor polynucleotide including a coding sequence of a gene target selected from the following: A20, HO-1, FAT-1, TNF-α receptor, CD39, hirudin, TFPI, EPCR, TBM, CD46, DAF (CD55), CD59, CR1, CTLA4, CD47, one or more class I HLAs in class I HLA. In some embodiments of the composition, the cleavage performed with the Cas12a protein causes the coding sequence to be inserted into the genome of the cell. In some embodiments of the composition, the insertion of the coding sequence into the genome of the cell causes the expression of the gene in the cell to increase.In some embodiments of the composition, the cleavage with the Cas12a protein causes disruption of a coding sequence of a gene target selected from the following in the genome of the cell: GGTA1, b4GalNT2, CMAH, GT (α(1,3)-galactosyltransferase), GHR, one or more class I SLAs of class I SLAs. In some embodiments of the composition, the disruption in the genome of the cell causes reduced expression of the gene in the cell. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description setting forth illustrative embodiments, in which the principles of the present disclosure are utilized, and the accompanying drawings. The drawings are not rendered to scale nor are they drawn to scale. The locations of the indicator labels are approximate.
[0028] Figure 1A , Figure 1B and Figure 1C An example of a V-type CRISPR-Cas12a guide RNA is shown.
[0029] Figure 2 Cas12a chRDNA guide / nucleoprotein complex cleavage of target polynucleotides is demonstrated.
[0030] Figure 3A-Figure 3I Various canonical and atypical nucleotides used for Cas12 chRDNA guides are shown.
[0031] Figure 4 Cas12a chRDNA guide / nucleoprotein complex cleavage of target polynucleotides is demonstrated.
[0032] Figure 5 The Cas12a crRNA guide is shown.
[0033] Figure 6 A Cas12a chRDNA guide including DNA bases in the activation region and a target binding sequence is shown.
[0034] Figure 7 A Cas12a chRDNA guide comprising DNA bases in the activation region and chemically modified nucleic acids and target binding sequences is shown.
[0035] Figure 8 The formation of the Cas12 chRDNA guide / nucleoprotein complex and the binding of the target polynucleotide are demonstrated.
[0036] Fig. 9Insertions or deletions (indels) generated in the target polynucleotide by the Cas12 chRDNA guide / nucleoprotein complex are shown.
[0037] Fig.10 Insertion of a donor polynucleotide sequence in a target polynucleotide by the Cas12 chRDNA guide / nucleoprotein complex is shown.
[0038] Fig.11 Cleavage of the target polynucleotide by the Cas12 chRDNA guide / nucleoprotein complex is demonstrated.
[0039] Fig.12 Tandem nicking of a target polynucleotide using two Cas12 chRDNA guide / nucleoprotein complexes and insertion of a donor polynucleotide sequence into the target polynucleotide are demonstrated. DETAILED DESCRIPTION
[0040] definition
[0041] The following definitions aid in understanding the present disclosure.
[0042] As used herein, the terms "guide" and "guide polynucleotide" refer to one or more polynucleotides that form a nucleoprotein complex with a Cas protein, wherein the nucleoprotein complex preferentially binds to a nucleic acid target sequence in a polynucleotide (relative to a polynucleotide that does not include a nucleic acid target sequence). Such guides may include ribonucleotide bases (e.g., RNA), deoxyribonucleotide bases (e.g., DNA), combinations of ribonucleotide bases and deoxyribonucleotide bases (e.g., RNA / DNA), nucleotide analogs, modified nucleotides, etc., as well as synthetic, naturally occurring, and non-naturally occurring modified backbone residues or bonds. Many such guides are known, such as, but not limited to, single guide RNA (including micro and truncated single guide RNAs), crRNA, dual guide RNAs, including, but not limited to, crRNA / tracrRNA molecules, etc., and their use depends on specific Cas proteins. For example, a "V-type CRISPR-Cas12-related guide" is a guide that specifically associates with a homologous Cas12 protein to form a nucleoprotein complex.
[0043] As used herein, a "CRISPR polynucleotide" is a polynucleotide sequence that includes a portion of a guide molecule. In some embodiments, a CRISPR polynucleotide comprises a targeting region and / or an activation region.
[0044] Regarding guide molecules, "spacers", "spacer sequences", "spacer elements" or "targeting regions" as used herein refer to polynucleotide sequences that can specifically hybridize with target nucleic acid sequences. The targeting region interacts with the target nucleic acid sequence through hydrogen bonding between complementary base pairs (ie, paired bases). The targeting region is bound to the selected nucleic acid target sequence. In some embodiments, the target sequence is a sequence within the genome of the cell, whether in vitro, ex vivo (such as in the production of CAR-T cells) or in vivo (such as in the case where the composition is directly administered to the subject). The targeting region determines the site-specific binding and nucleolytic cleavage position of the Cas12 protein. The variability of the functional length of the targeting region is known in the art.
[0045] With respect to guide molecules, the term "activation region" refers to a portion of a polynucleotide that is capable of associating or binding to a Cas12 polypeptide (such as a Cas12a polypeptide).
[0046] As used herein, the terms "base analogs," "atypical bases," and "chemically modified bases" refer to compounds that have structural similarities to typical purine or pyrimidine bases found in DNA or RNA. Base analogs may contain modified sugars and / or modified nucleobases, as compared to purine or pyrimidine bases naturally found in DNA or RNA. In some embodiments, the base analog is inosine or deoxyinosine, such as 2'-deoxyinosine. In other embodiments, the base analog is a 2'-deoxynucleoside, a 2'-ribonucleoside, a 2'-deoxyribonucleotide, or a 2'-ribonucleotide, wherein the nucleobase comprises a modified base (e.g., xanthine, uridine, oxanine (oxanosine), 7-methylguanosine, dihydrouridine, 5-methylcytidine, C3 spacer, 5-methyl dC, 5-hydroxybutyl-2'-deoxyuridine, 5-nitroindole, 5-methylisodeoxycytosine, isodeoxyguanosine, deoxyuridine, isodeoxycytidine, other 0-1 purine analogs, N-6-hydroxyaminopurine, agarosin, 7-deazahypoxanthine, other 7-deazapurines, and 2-methylpurines). In some embodiments, the base analog can be selected from the group consisting of: 7-deaza-2'-deoxyinosine, 2'-aza-2'-deoxyinosine, PNA-inosine, morpholino-inosine, LNA-inosine, phosphoramidite-inosine, 2'-O-methoxyethyl-inosine and 2'-OMe-inosine. The term "base analog" also includes, for example, 2'-deoxyribonucleosides, 2'-ribonucleosides, 2'-deoxyribonucleotides or 2'-ribonucleotides, wherein the nucleobase is substituted hypoxanthine. For example, substituted hypoxanthine can be substituted by halogen (such as fluorine or chlorine). In some embodiments, the base analog can be fluoroinosine or chloroinosine, such as 2-chloroinosine, 6-chloroinosine, 8-chloroinosine, 2-fluoroinosine, 6-fluoroinosine or 8-fluoroinosine. In other embodiments, the base analog is deoxyuridine. In other embodiments, the base analogs are nucleic acid mimetics (eg, artificial nucleic acids and xenogeneic nucleic acids (XNA)).
[0047] As used herein, the term "CRISPR hybrid RNA / DNA guide" (chRDNA) refers to a polynucleotide guide molecule comprising a targeting region, wherein the polynucleotide comprises RNA and a DNA designed as a polynucleotide.
[0048] As used herein, the term "Cas12-chRDNA guide nucleoprotein complex" refers to a chRDNA guide molecule that forms a nucleoprotein complex with a Cas12 protein, wherein the nucleoprotein complex is capable of site-specific binding to a nucleic acid target sequence that is complementary to a nucleic acid target binding sequence present in the chRDNA guide molecule.
[0049] "Linker element nucleotide sequence", "linker nucleotide sequence" and "linker polynucleotide" are used interchangeably herein and refer to a sequence of one or more nucleotides covalently linked to a first nucleic acid sequence (5'-linker nucleotide sequence-first nucleic acid sequence-3'). In some embodiments, a linker nucleotide sequence connects two separate nucleic acid sequences to form a single polynucleotide (e.g., 5'-first nucleic acid sequence-linker nucleotide sequence-second nucleic acid sequence-3').
[0050] As used herein, the term "homologous" generally refers to a Cas12 protein (e.g., Cas12a) and one or more V-type CRISPR-Cas12-associated guides (e.g., Cas12 chRDNA guides) that are capable of forming a nucleoprotein complex capable of site-directed binding to a nucleic acid target sequence that is complementary to a nucleic acid target binding sequence present in one of the one or more guides.
[0051] The terms "engineered," "genetically engineered," "genetically modified," "recombinant," "modified," "non-naturally occurring," and "non-natural" refer to intentional manipulation of the genome of an organism or cell by humans. These terms encompass genome modification methods, including genome editing as defined herein, as well as techniques to alter gene expression or inactivation, enzyme engineering, directed evolution, knowledge-based design, random mutagenesis methods, gene shuffling, codon optimization, and the like. Methods for genetic engineering are known in the art.
[0052] As used herein, a Cas12 protein is said to "target" a polynucleotide if the Cas12 guide / nucleoprotein complex binds to or cleaves a polynucleotide at a nucleic acid target sequence within the polynucleotide.
[0053] As used herein, "protospacer adjacent motif" or "PAM" refers to a double-stranded nucleic acid sequence that includes a Cas12 protein binding recognition sequence, wherein the amino acids of the Cas12 protein directly interact with the recognition sequence (e.g., the Cas12a protein interacts with PAM 5'-TTTN-3' or PAM 5'-TTTV-3'). The PAM sequence is located on the non-target strand and can be 5' or 3' to the target complement sequence (e.g., in the CRISPR-Cas12a system, the PAM 5'-TTTN-3' or PAM 5'-TTTV-3' sequence is located on the non-target strand and is 5' to the target complement sequence).
[0054] "Target", "target sequence", "nucleic acid target sequence", "target nucleic acid sequence" and "on-target sequence" are used interchangeably herein and refer to a nucleic acid sequence that is completely or partially complementary to a nucleic acid target binding sequence (e.g., a targeting region) of a Cas12 polynucleotide. Typically, the nucleic acid target binding sequence is selected to be 100% complementary to the nucleic acid target sequence to which the Cas12 nucleoprotein complex binds; however, in order to weaken the binding to the nucleic acid target sequence, a lower percentage of complementarity can be used.
[0055] "Donor polynucleotide", "donor oligonucleotide", "donor template", "non-viral donor" and "non-viral template" are used interchangeably herein and can be a double-stranded polynucleotide (e.g., DNA), a single-stranded polynucleotide (e.g., DNA or RNA), or a combination thereof. The donor polynucleotide may include homology arms flanking the inserted sequence (e.g., a DSB in DNA). The length of the homology arms on each side may vary to ensure that the desired level of hybridization is achieved under the conditions used.
[0056] As used herein, "homologous directed repair" (HDR) refers to DNA repair that occurs during the repair of a DSB in a cell, such as in DNA. HDR requires nucleotide sequence homology, and uses a donor polynucleotide to repair a sequence in which a DSB occurs (e.g., within a target DNA sequence). For example, a donor polynucleotide can be used to repair a break in a target DNA sequence, wherein the repair causes genetic information (e.g., a polynucleotide sequence) to be transferred from the donor polynucleotide at or near the site of the DNA break. Therefore, new genetic information (e.g., a polynucleotide sequence) can be inserted or replicated at the target DNA sequence.
[0057] As used herein, "homologous-independent target integration" (HITI) refers to DNA repair that occurs in a cell, for example, during the repair of a DSB in DNA. Unlike HDR, HITI does not require nucleotide sequence homology, and uses a donor polynucleotide to repair the sequence in which the DSB occurs (e.g., within a target DNA sequence). HITI causes genetic information to be transferred from, for example, a donor polynucleotide to a target DNA sequence. Thus, new genetic information (e.g., a polynucleotide sequence) can be inserted or replicated at the target DNA sequence.
[0058] A "genomic region" is a segment of a chromosome in the genome of a host cell that is present on either side of a nucleic acid target sequence site, or alternatively also includes a portion of a nucleic acid target sequence site. The homology arms of the donor polynucleotide have sufficient homology to perform homologous recombination with the corresponding genomic region.
[0059] As used herein, "non-homologous end joining" (NHEJ) refers to repairing DSBs in DNA by directly joining one end of the break to the other end of the break without the need for a donor polynucleotide. NHEJ is a DNA repair pathway that can be used in cells to repair DNA without the use of a repair template. In the absence of a donor polynucleotide, NHEJ typically causes random insertions or deletions of nucleotides at the site of the DSB.
[0060] "Microhomology-mediated end joining" (MMEJ) is a pathway for repairing DSBs in DNA. MMEJ involves the deletion of the flanking DSB and the alignment of microhomology sequences within the break site before joining. MMEJ is genetically defined and requires, for example, the activity of CtIP, poly (ADP-ribose) polymerase 1 (PARP1), DNA polymerase θ (Polθ), DNA ligase 1 (Lig 1), or DNA ligase 3 (Lig 3). Additional gene components are known in the art. See, for example, Sfeir et al. (Trends in Biochemical Sciences, 2015, 40: 701-714).
[0061] As used herein, "DNA repair" encompasses any process by which a cellular mechanism repairs damage to a DNA molecule contained in a cell. The repaired damage may include single-strand breaks or double-strand breaks (DSBs). There are at least three mechanisms for repairing DSBs: HDR, NHEJ, and MMEJ. "DNA repair" is also used herein to refer to DNA repair caused by human manipulation, wherein a target locus is modified, for example, by insertion, deletion, or substitution (all of which represent forms of genome editing) of nucleotides.
[0062] As used herein, the terms "regulatory sequence," "regulatory element," and "control element" are interchangeable and refer to polynucleotide sequences located upstream (5' non-coding sequence), internal, or downstream (3' non-translated sequence) of a polynucleotide target to be expressed. For example, regulatory sequences affect the timing of transcription, the amount or level of transcription, RNA processing or stability, and / or translation of associated structural nucleotide sequences. Regulatory sequences may include activator binding sequences, enhancers, introns, polyadenylation recognition sequences, promoters, transcription start sites, repressor binding sequences, stem-loop structures, translation start sequences, internal ribosome entry sites (IRES), translation leader sequences, transcription termination sequences (e.g., polyadenylation signals and poly-U sequences), translation termination sequences, primer binding sites, and the like.
[0063] As used herein, the term "operably linked" refers to a functional relationship between polynucleotide sequences or amino acid sequences. For example, if a regulatory sequence (e.g., a promoter or enhancer) regulates or helps regulate the transcription of a polynucleotide, the regulatory sequence is "operably linked" to the polynucleotide encoding the gene product. Operably linked regulatory elements are usually adjacent to the coding sequence. However, if separated from the promoter by at most several kilobases or more, the enhancer can play a role. Therefore, some regulatory elements can be operably linked to a polynucleotide sequence, but not adjacent to the polynucleotide sequence. Similarly, translation regulatory elements help regulate protein expression from a polynucleotide.
[0064] As used herein, the term "regulation" refers to a change in the quantity, degree, or amount of a function. For example, as disclosed herein, the Cas12-guide / nucleoprotein complex can regulate the activity of a promoter sequence by binding to a nucleic acid target sequence at or near the promoter. Depending on the effects that occur after binding, the Cas12 guide / nucleoprotein complex can induce, enhance, contain, or inhibit transcription of a gene operably linked to a promoter sequence. Therefore, "regulation" of gene expression includes both gene activation and gene repression.
[0065] "Adoptive cells" refer to cells that can be or have been genetically modified for use in cell therapy treatment.
[0066] "Stem cell" refers to a cell with the ability to self-renew, i.e., the ability to undergo many cycles of cell division while remaining in an undifferentiated state. Stem cells can be omnipotent, multipotent, multipotent, oligopotent or unipotent. Stem cells are embryonic stem cells, fetal stem cells, amniotic stem cells, adult stem cells or induced pluripotent stem cells.
[0067] "Induced pluripotent stem cells" (iPSC) refer to a type of pluripotent stem cells artificially derived from non-pluripotent stem cells (usually somatic cells). Pluripotent stem cells can be edited with the Cas12 chRDNA guide / nucleoprotein complex before or after differentiation. iPSCs can be further modified by introducing exogenous genes or sequences into the genome (such as sequences encoding CAR) before or after differentiation.
[0068] "Hematopoietic stem cells" refer to undifferentiated cells that are capable of differentiating into cells of the hematopoietic lineage, such as lymphocytes.
[0069] "Lymphocyte" refers to a leukocyte (leukocyte / white blood cell) that is part of the vertebrate immune system. The term "lymphocyte" also encompasses hematopoietic stem cells that produce lymphocytes. Lymphocytes include: T cells for cell-mediated cytotoxic adaptive immunity, such as CD4+ and / or CD8+ cytotoxic T cells; α / βT cells and γ / δT cells; regulatory T cells, such as Treg cells; natural killer (NK) cells that play a role in cell-mediated cytotoxic innate immunity; and B cells for humoral, antibody-driven adaptive immunity; NK / T cells; cytokine-induced killer cells (CIK cells); and antigen presenting cells (APCs), such as dendritic cells. Lymphocytes can be mammalian cells, such as human cells.
[0070] Tumor infiltrating lymphocytes (TIL) are also encompassed in the term "lymphocytes" as used herein. TILs are immune cells that have infiltrated the interior and surrounding environment of a tumor ("tumor microenvironment"). The term "lymphocytes" also encompasses genetically modified T cells and NK cells (CAR-T cells and CAR-NK cells).
[0071] The terms "subject," "individual," or "patient" are used interchangeably herein and refer to humans and other primates, as well as other mammals, farm animals, livestock, and laboratory animals. In some embodiments, the cell is derived from the subject (e.g., a lymphocyte, stem cell, progenitor cell, or tissue-specific cell). In some embodiments, the subject is a non-human subject.
[0072] The term "effective amount" or "therapeutically effective amount" of a composition or medicament (such as the genetically engineered adoptive cells provided herein) refers to a sufficient amount of a composition or medicament for providing a desired response. Preferably, an effective amount will prevent, avoid or eliminate one or more harmful side effects. Such a response will depend on the specific disease in question. For example, in patients using adoptive cell therapy to treat cancer, the desired response may include preventing, avoiding or eliminating one or more of the following: treating or preventing graft-versus-host disease (GvHD), host-versus-graft rejection, cytokine release syndrome (CRS), cytokine storms, and a reduction in the oncogenic transformation of the genetically modified cells administered. The precise therapeutic amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, and the specific modified lymphocytes used, the mode of administration, etc. The appropriate "effective amount" in any individual case can be determined by a person of ordinary skill in the art using routine experiments.
[0073] "Treatment" or "treating" a particular disease (such as a cancer condition or GvHD) includes: preventing the disease, e.g., preventing the development of the disease or causing the disease to occur at a lesser intensity in a subject that may be susceptible to the disease but does not yet develop or show symptoms of the disease; inhibiting the disease, e.g., slowing the rate of development, arresting development, or reversing the disease state; and / or alleviating the symptoms of the disease, e.g., reducing the number of symptoms experienced by a subject.
[0074] The present disclosure relies on conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics, and recombinant polynucleotides as taught, for example, in the following standard publications: Sambrook, Joseph. Molecular Cloning: a Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 2001; EA Greenfield (Antibodies: A Laboratory Manual, 2014, 2nd edition, Cold Spring Harbor Laboratory Press, ISBN 978-1-936113-81-1); RI Freshney (Culture of animal cells: A Manual of Basic Technique and Specialized Applications, 2016, 7th edition, Wiley-Blackwell, ISBN 978-1-936113-81-1). 978-1118873656); JM Walker (Methods in Molecular Biology (series), Humana Press, ISSN 1064-3745); Green et al. (Molecular Cloning: A Laboratory Manual, 2012, 4th edition, Cold Spring Harbor Laboratory Press, ISBN 978-1605500560).
[0075] CRISPR V-type system
[0076] Clustered regularly interspaced short palindromic repeats (CRISPR) and associated CRISPR-associated proteins (Cas proteins) constitute the CRISPR-Cas system. The classification of CRISPR-Cas systems has undergone many iterations. Makarova et al. (Nature Reviews: Microbiology, 2020, 18: 67-83) proposed a classification system that takes into account characteristic cas genes specific to individual types and subtypes of CRISPR-Cas systems. The classification also takes into account sequence similarity between multiple shared Cas proteins, phylogeny of the most conserved Cas proteins, gene organization, and structure of the CRISPR array. This method provides a classification scheme that divides CRISPR-Cas systems into two different categories: Class 1 and Class 2.
[0077] In the Class 2 V-type system, crRNA and target binding involve Cas12, as does target nucleic acid cleavage. For example, the RuvC-like nuclease domain of Cas12a cleaves both strands of the target nucleic acid in a staggered configuration, thereby generating 5' overhangs, which contrast to the blunt ends generated by Cas9 cleavage. These 5' overhangs can facilitate DNA insertion by homologous recombination methods.
[0078] Other proteins associated with V-type crRNA and target binding and cleavage include Cas12b (formerly C2c1) and Cas12c (formerly C2c3). Cas12b and Cas12c proteins are similar in length to CRISPR 2 type II Cas9 and CRISPR 2 type V Cas12a proteins, ranging from about 1,100 amino acids to about 1,500 amino acids. C2c1 and C2c3 proteins also contain RuvC-like nuclease domains and have structures similar to Cas12a. C2c1 protein is similar to Cas9 protein in that crRNA and tracrRNA are required for target binding and cleavage, but its optimal cleavage temperature is 50 ° C. C2c1 protein targets AT-rich PAM, which is similar to Cas12a, located at 5' of the target sequence. See, for example, Shmakov et al. (Molecular Cell, 2015, 60 (3): 385-397).
[0079] CRISPR type V subtypes contain Cas12 proteins and show extensive sequence and size diversity; however, Cas12 subtypes share a common evolutionary origin with the TnpB nuclease encoded by the IS605-like transposon. Due to the low sequence similarity of Cas12 proteins and the possibility of evolution through multiple independent recombination events, the classification of Cas12 proteins into their corresponding subtypes has given rise to a variety of naming conventions. Table 1 shows the classification and names of type V Cas12 proteins, as well as their approximate sizes, guide requirements, preferred target polynucleotides, and representative source organisms.
[0080]
[0081]
[0082] Cas12 homologs can be identified using sequence similarity search methods known to those skilled in the art. Typically, the Cas12 protein can interact with a homologous Cas12 guide to form a Cas12 guide / nucleoprotein complex that can bind to a target nucleic acid sequence. In some embodiments of the present disclosure, the Cas12 protein or its homolog is a Cas12a protein or its homolog.
[0083] Cas12a proteins include but are not limited to Cas12a from the following: Thrifty bacteria GWC2011_GWC2_44_17 (PbCpf1), Lachnospiraceae bacteria MC2017 (Lb3 Cpf1), Butyrivibrio proteolyticus (BpCpf1), Allopatricial bacteria GW2011_GWA_33_10 (PeCpf1), Acidovaricoccus BV3L6 (AsCpf1), Porphyromonas macaques (PmCpf1), Lachnospiraceae bacteria ND2006 (LbCpf1), Porphyromonas canis oralis (PcCpf1), Prevotella glycolyticus (PdCp f1), Moraxella bovis 237 (MbCpf1), Smithia sp. SC_K08D17 (SsCpf1), Leptospira indica (LiCpf1), Lachnospiraceae MA2020 (Lb2Cpf1), Francisella novicida U112 (FnCpf1), Methanoplasma candidate termite (CMtCpf1), and Eubacterium exetilis (EeCpf1).
[0084] In the V-type system, nucleic acid target sequence binding generally involves Cas12 protein and crRNA, just like nucleic acid target sequence cutting. In the V-type system, the RuvC-like nuclease domain of Cas12 protein cuts the two chains of nucleic acid target sequence in a sequential manner (see Swarts et al. (Mol. Cell, 2017, 66: 221-233)), thereby generating 5' protruding ends, which are in sharp contrast to the blunt ends generated by Cas9 protein cutting.
[0085] The Cas12 protein cleavage activity of the V-type system can be independent of tracrRNA (e.g., VA type); and some V-type systems only require a single crRNA with a stem-loop structure that forms an internal duplex. The Cas12 protein binds to crRNA in a sequence-specific and structure-specific manner by recognizing the stem-loop and the sequence adjacent to the stem-loop, most notably the nucleotide at the 5' of the spacer sequence that hybridizes with the nucleic acid target sequence. The length of this stem-loop structure is generally in the range of 15 to 22 nucleotides. Substitutions that destroy this stem-loop duplex eliminate the cleavage activity, while other substitutions that do not destroy the stem-loop duplex do not eliminate the cleavage activity. Some V-type systems require hybridization between crRNA and tracrRNA, such as V-F1, VG, VC, VE (CasX), VK, and VB types. See, for example, Yan et al. (Science, 2019, 363 (6422): 88-91).
[0086] Cas12 Wizard
[0087] CRISPR Cas12chRDNA guides capable of forming nucleoprotein complexes with homologous Cas12 proteins (such as Cas12a proteins) have been described in international patent application serial number PCT / US21 / 55394 for CRISPR V-type systems containing DNA polynucleotides and guides and methods of making and using the same, filed on October 18, 2021. The complexes described therein are capable of targeting sequences complementary to spacer sequences.
[0088] Figure 1A An example of an Acidaminococcus BV316 Cas12a guide molecule comprising: an activation region ( Figure 1A , 101), which includes a stem-loop duplex ( Figure 1A , 102); and a spacer sequence ( Figure 1A , 103), which includes a target binding sequence ( Figure 1A , 104). Figure 1B Alternative Cas12a guide molecules are presented that include: an activation region ( Figure 1B , 105), which includes a stem-loop duplex ( Figure 1B , 106); and a spacer sequence ( Figure 1B , 107), which includes a target binding sequence ( Figure 1B , 108) and 3' extension ( Figure 1B , 109). 3' extension ( Figure 1B , 109) can be connected to the spacer sequence ( Figure 1B , 107) connection. Figure 1C Alternative Cas12a guide molecules are presented that include: an activation region ( Figure 1C , 110), which includes a stem-loop duplex ( Figure 1C , 111); and linker nucleotide ( Figure 1C , 114) and 5' extension ( Figure 1C , 115); and a spacer sequence ( Figure 1C , 112), which includes a target binding sequence ( Figure 1C , 113).
[0089] In the Cas12 chRDNA guide molecules disclosed herein, the targeting region and or the activation region alone may include DNA, RNA, or a mixture of DNA and RNA. In certain embodiments, the targeting and activation regions may also include other base analogs, modified nucleotides, abasic sites, etc., as well as synthetic, naturally occurring and non-naturally occurring modified backbone residues or bonds or combinations thereof.
[0090] In some embodiments, the activation region is 10-25 bases in length, including an optional abasic site.
[0091] In some embodiments, the targeting region is 10-30 bases in length, including an optional abasic site.
[0092] Figure 2 Demonstrated interactions with target binding sequences including ( Figure 2 , 205) of the homologous Cas12a chRDNA guide molecule ( Figure 2 , 204) bound Cas12a protein ( Figure 2 , 206). The Cas12a chRDNA guide / nucleoprotein complex unwinds the target polynucleotide including the target sequence, and the target binding sequence of the Cas12 chRDNA guide molecule ( Figure 2 , 205) through hydrogen bonding ( Figure 2 , indicated by a vertical line between polynucleotides) and the target sequence ( Figure 2 , 207) connection. Figure 2 In the present invention, the target polynucleotide comprises a target sequence ( Figure 2 , 207) target chain ( Figure 2 , 201) and including the PAM sequence ( Figure 2 , 203) non-target strand ( Figure 2 , 202). PAM sequence ( Figure 2 , 203) usually occurs in the non-target strand ( Figure 2, 202) on the target sequence ( Figure 2 , 207) upstream (i.e., in the 5' direction). Cas12achRDNA guide molecule target binding sequence ( Figure 2 , 205) and the target sequence ( Figure 2 , 207) causes the formation of hydrogen bonds between the target chain ( Figure 2 , 201) and non-target strands ( Figure 2 , 202) of staggered cutting ( Figure 2 , 208).
[0093] Figure 3A-Figure 3I Various typical and atypical nucleotides for the Cas12 chRDNA guide molecules disclosed herein are shown. Table 2 shows Figure 3A-Figure 3I A series of indicator marks used in
[0094]
[0095]
[0096] Figure 4 Demonstrated interactions with target binding sequences including ( Figure 4 , 405) homologous Cas12a chRDNA guide molecule ( Figure 4 , 404) bound Cas12a protein ( Figure 4 , 406), wherein the target binding sequence ( Figure 4 , 405) including non-RNA nucleotides ( Figure 4 , 409), such as Figure 3B-Figure 3I Typical and non-typical nucleotides are shown in Figure 2. The Cas12a chRDNA guide / nucleoprotein complex unwinds the target polynucleotide including the target sequence, and the target binding sequence ( Figure 4 , 405) through hydrogen bonding ( Figure 4 , indicated by a vertical line between polynucleotides) and the target sequence ( Figure 4 , 407) connection. Figure 4 In the present invention, the target polynucleotide comprises a target sequence ( Figure 4 , 407) target chain ( Figure 4 , 401) and including the PAM sequence ( Figure 4 , 403) non-target strand ( Figure 4 , 402). PAM sequence ( Figure 4 , 403) usually occurs in the non-target strand ( Figure 4 , 402) on the target sequence ( Figure 4 , 407) upstream (i.e., in the 5' direction). The target binding sequence of the chRDNA guide molecule ( Figure 4 , 405) and the target sequence ( Figure 4, 407) causes the formation of hydrogen bonds between the target chain ( Figure 4 , 401) and non-target strand ( Figure 4 , 402) interleaved cutting ( Figure 4 , 408).
[0097] Figure 5 An example of an Acidaminococcus (strain BV3L6) Cas12a crRNA guide molecule comprising: an activation region ( Figure 5 , 501), which includes a stem-loop duplex ( Figure 5 , 502); and spacer ( Figure 5 , 503), which includes a target binding sequence ( Figure 5 , 504). Activation area ( Figure 5 , 501) and spacer ( Figure 5 , 503) are labeled starting from the 5' end of the guide molecule, where the activation region and the target binding region each include RNA.
[0098] Figure 6 An example of an Acidaminococcus (strain BV3L6) Cas12a chRDNA guide molecule comprising: an activation region ( Figure 6 , 601), which includes a stem-loop duplex ( Figure 6 , 602); and spacer ( Figure 6 , 603), which includes a target binding sequence ( Figure 6 , 604). Spacer ( Figure 6 , 603) in the activation region ( Figure 6 , 601) is labeled starting from the 5' end of the guide molecule, where the activation region includes a mixture of RNA (white fill) and DNA (gray fill), and the target binding sequence includes a mixture of RNA (white fill) and DNA (gray fill).
[0099] Figure 7 An example of an Acidaminococcus (strain BV3L6) Cas12a chRDNA guide molecule comprising: an activation region ( Figure 7 , 701), which includes a stem-loop duplex ( Figure 7 , 702); and spacer ( Figure 7 , 703), which includes a target binding sequence ( Figure 7 , 704). Activation area ( Figure 7 , 701) and spacer ( Figure 7, 703) are marked starting from the 5' end of the guide molecule, where the activation region includes a mixture of RNA (white fill) and DNA (gray fill). The Cas12a chRDNA guide molecule further includes other atypical nucleotides, such as chemically modified sugar nucleotides ( Figure 7 , 705), abasic ribonucleotides ( Figure 7 , 706), deoxyribonucleotides with chemically modified backbones ( Figure 7 , 707), ribonucleotides with chemically modified backbones ( Figure 7 , 708) and abasic deoxyribonucleotides ( Figure 7 , 709).
[0100] Figure 8 The formation of the Cas12 chRDNA guide / nucleoprotein complex is shown, in which the Cas12 protein ( Figure 8 , 801) and Cas12 chRDNA guide molecule ( Figure 8 , 802) binds to form the Cas12 chRDNA guide / nucleoprotein complex ( Figure 8 , 803). Cas12 chRDNA guide / nucleoprotein complex ( Figure 8 , 803) and the target polynucleotide ( Figure 8 , 804), wherein the target polynucleotide comprises a target sequence complementary to the target binding sequence of the Cas12 chRDNA guide molecule, and the target binding sequence of the Cas12 chRDNA guide molecule is complementary to the target sequence ( Figure 8 , 805) form hydrogen bonds.
[0101] Fig. 9 The invention shows that insertions or deletions (indels) are generated in target polynucleotides by Cas12 chRDNA guide / nucleoprotein complexes, wherein the Cas12 chRDNA guide molecule ( Fig. 9 , 902) complexed Cas12 protein ( Fig. 9 , 901) and including PAM ( Fig. 9 , 904) target polynucleotide ( Fig. 9 , 903) binds, and the target polynucleotide is cleaved by the Cas12 chRDNA guide / nucleoprotein complex ( Fig. 9 , 905). After targeting occurs, the Cas12 chRDNA guide / nucleoprotein complex dissociates from the target polynucleotide ( Fig. 9 , 906), wherein the target polynucleotide is relative to the PAM ( Fig. 9 , 904) includes the upstream (ie, in the 5' direction) strand ( Fig. 9 , 907) and the downstream (i.e., in the 3' direction) strand ( Fig. 9, 908). Cellular DNA repair mechanisms repair the target polynucleotide by inserting or deleting sequences around the cleavage site ( Fig. 9 , 910) to repair the target polynucleotide. The upstream strand ( Fig. 9 , 911) and downstream chain ( Fig. 9 , 912) are rejoined, and the edited target polynucleotide ( Fig. 9 , 914) include insertions or deletions at the cleavage site ( Fig. 9 , 913), wherein the edited target polynucleotide has a different sequence relative to the unedited target polynucleotide. In some embodiments, the insertion or deletion (indel) produced by the Cas12chRDNA guide / nucleoprotein complex in the target polynucleotide occurs in the cell.
[0102] Fig.10 The donor polynucleotide sequence is shown to be incorporated into the target polynucleotide, wherein the Cas12 chRDNA guide molecule ( Fig.10 , 1002) complexed Cas12 protein ( Fig.10 , 1001) and including PAM ( Fig.10 , 1004) of the target polynucleotide ( Fig.10 , 1003) binds, and the target polynucleotide is cleaved by the Cas12 chRDNA guide / nucleoprotein complex ( Fig.10 , 1005). After targeting occurs, the Cas12 chRDNA guide / nucleoprotein complex dissociates from the target polynucleotide ( Fig.10 , 1006), wherein the target polynucleotide is relative to the PAM ( Fig.10 , 1004) includes the upstream (ie, in the 5' direction) strand ( Fig.10 , 1007) and the downstream (i.e., in the 3' direction) strand ( Fig.10 , 1008), and wherein a donor polynucleotide is provided ( Fig.10 , 1009). Cellular DNA repair mechanisms use donor polynucleotides ( Fig.10 , 1011) repair target polynucleotide ( Fig.10 , 1010). The resulting edited target polynucleotide ( Fig.10 , 1010) includes a donor sequence at the target site ( Fig.10 , 1011). In some embodiments, incorporation of the donor polynucleotide sequence into the target polynucleotide occurs within a cell.
[0103] Fig.11 The target polynucleotide is shown to be nicked, wherein the DNA bases ( Fig.11 , 1106) of the Cas12 chRDNA guide molecule ( Fig.11 , 1102) complexed Cas12 protein ( Fig.11 , 1101) and including PAM ( Fig.11 , 1104) target polynucleotide ( Fig.11 , 1103) binds, and the target polynucleotide is nicked by the Cas12 chRDNA guide / nucleoprotein complex only in one strand of the target polynucleotide ( Fig.11 , 1105).
[0104] Fig.12 The invention demonstrates the use of two nicking Cas12 chRDNA guide / nucleoprotein complexes to generate staggered double-strand breaks in a target polynucleotide, wherein the first Cas12 chRDNA guide / nucleoprotein complex binds to the upstream (i.e., in the 5' direction) target sequence of the target polynucleotide ( Fig.12 , 1201) binds to generate a first nick in the target polynucleotide ( Fig.12 , 1202), and the second Cas12 chRDNA guide / nucleoprotein complex binds to the downstream (i.e., in the 3' direction) target sequence of the target polynucleotide ( Fig.12 , 1203) binds to generate a second nick in the target polynucleotide ( Fig.12 , 1204). After tandem nicking occurs, the cleaved target polynucleotide includes an upstream (ie, in the 5' direction) strand ( Fig.12 , 1205) and the downstream (i.e., in the 3' direction) strand ( Fig.12 , 1206). A donor polynucleotide is provided, and the cellular DNA repair machinery uses the donor polynucleotide ( Fig.12 , 1208) repair target polynucleotide ( Fig.12 , 1207). The resulting edited target polynucleotide ( Fig.12 , 1209) includes a donor sequence at the tandem nicking site ( Fig.12 , 1210). In some embodiments, the generation of staggered DSBs in a target polynucleotide using a two-nicked Cas12chR DNA guide / nucleoprotein complex occurs intracellularly.
[0105] Methods for designing specific Cas12 chRDNA guide molecules into which deoxyribonucleotides and optionally additional modifications (such as base analogs, modified nucleotides, abasic sites, modified backbone residues or bonds or combinations thereof) can be designed, as described in, for example, sequence number PCT / US21 / 55394. In short, in order to design the Cas12 guide, the genomic sequence of the gene to be targeted is first identified. The exact region to be targeted by the selected gene will depend on the specific application. For example, in order to activate or repress the target gene, Cas12 can target the promoter or 5' constitutively expressed exon that drives the expression of the gene to reduce the possibility of removing the targeting region from mRNA due to alternative splicing. Other exons in the N-terminal portion can be targeted because the frameshift mutation here will produce a non-functional protein product. Exons encoding essential protein domains can also be targeted. For gene editing using HDR, the target sequence should be close to the desired editing position. In this case, the position desired to be edited is identified and the target sequence is selected nearby.
[0106] In some embodiments, the Cas12 chRDNA guide can be designed to bind outside the cleavage site of the Cas12 protein, so that the target nucleic acid can be released from the Cas12 nucleoprotein complex. In some embodiments, the Cas12 chRDNA guide can be designed to bind inside the cleavage site of the Cas12 protein. In this case, the target nucleic acid can be bound to the Cas12 nucleoprotein complex.
[0107] In some embodiments of the Cas12 chRDNA guide molecule, the targeting region, the activation region, or both contain deoxyribonucleotides or modified nucleotides. In some embodiments, the Cas12a chRDNA guide includes one or more, for example, 23 or fewer deoxyribonucleotides. In some embodiments, all deoxyribonucleotides in the targeting region of the chRDNA form typical base pairs with the target sequence. In some embodiments, at least one of the deoxyribonucleotides in the targeting region of the chRDNA does not form a typical base pair with the target sequence, or forms an atypical base pair with the target sequence.
[0108] Cas12 protein
[0109] The Cas12 protein disclosed herein includes, but is not limited to, Cas12 wild-type protein derived from a V-type CRISPR-Cas system, a modified Cas12 protein, a variant of a Cas12 protein, a Cas12 ortholog, and a combination thereof. In some embodiments, the Cas12 protein is a wild-type Cas12a protein, a modified Cas12a protein, a variant of a Cas12a protein, a Cas12a ortholog, or a combination thereof. .
[0110] Cas12 protein is usually composed of six domains, corresponding to REC1, REC2, PAM interaction (PI), nuclease (Nuc), wedge (WED) and RuvC domains. See, for example, Yamano et al. (Cell, 2016, 165 (4): 949-962). WED domain and RuvC domain can have a three-part sequence architecture interrupted by sequences from other domains. For example, amino acid coccus Cas12a WED domain sequence is interrupted by REC1, REC2 and PI domain sequence. Additionally, some subtypes of Cas12 protein include adjacent RuvC domain sequences or bridge helical domains occurring between them.
[0111] In order to produce modified Cas12 protein, the region of Cas12 protein can be modified to regulate the activity of Cas12 protein. For example, the region corresponding to the residues of PI domain (598-718) and WED domain (526-597 and 719-883) of aminoacidococcus (strain BV3L6) Cas12a protein can be modified to change PAM specificity. See, for example, Tóth et al. (Nucleic Acid Research, 2020, 48 (7): 3722-3733). The region inthe Acidaminococcus spp. (strain BV3L6) can modify the Cas12a protein corresponding to the residues of REC1 (24-319) and REC2 (320-526) domains to change target engagement and cutting dynamics. The regions of REC1 (226-304) and REC2 (368-435) domains directly interact with the target binding sequence and the PAM distal end of the target sequence, and can be engineered to modify the efficiency of target sequence cutting. The regions of Nuc domain (1066-1261) and RuvC domain (940-956, 957-1065 and 1261-1307) can be modified to change the target strand, non-target strand or target strand and non-target strand cutting efficiency of the target sequence. Engineering these regions can include introducing mutations, using corresponding regions from other Cas12 orthologs to replace, delete, insert, etc.
[0112] Modified Cas12 protein can be used in combination with Cas12 chRDNA guide molecules to change the activity or specificity of Cas12 protein. In some cases, when compounded with Cas12 chRDNA guide molecules, Cas12 protein can be modified to provide enhanced activity or specificity, wherein Cas12 modification occurs in REC1, REC2, RuvC, WED and / or Nuc domains. In some cases, when compounded with Cas12 chRDNA guide molecules, Cas12 protein can be modified to provide enhanced activity or specificity, wherein Cas12a modification occurs in 226-304, 368-435, 940-956, 978-1158, 1159-1180 and 1181-1298 regions (based on amino acid coccus Cas12a sequence numbering).
[0113] In some embodiments, the Cas12 protein is an nCas12 protein as a nuclease-deficient variant, also referred to as "nicked Cas12" or "Cas12 nickase". Such molecules lack a portion of the endonuclease activity and can therefore only nick one strand of the target nucleic acid. See, for example, Jinek et al. (Science, 2012, 337: 816-821). For example, this can be achieved by introducing mutations into the RuvC nuclease domain. Non-limiting examples of such modifications may include D917A, E1006A, and D1225A of the RuvC nuclease domain of the F. novicida Cas12a protein. It should be understood that mutations of other catalytic residues may also be performed by those skilled in the art to reduce the activity of the RuvC nuclease domain. The resulting nCas12 protein cannot cut double-stranded DNA, but retains the ability to compound with the guide molecule, bind to the target DNA sequence, and nick only one strand of the target DNA. Targeting specificity is determined by the Cas12 protein bound to the PAM sequence and the base pairing of the guide molecule complementary to the genomic locus. In some embodiments of the present disclosure, the nCas12 protein is an nCas12a protein.
[0114] In some embodiments, the Cas12 protein is a dCas12 protein that is a nuclease inactive variant, also referred to as a "catalytically inactive Cas12 protein," "enzymatically inactive Cas12," "catalytically dead Cas12," or "dead Cas12." Such molecules lack endonuclease activity and can therefore be used to regulate genes in an RNA-guided manner. See, for example, Jinek et al. (Science, 2012, 337: 816-821). Those skilled in the art can mutate catalytic residues to eliminate the activity of the RuvC domain. The resulting dCas12 protein cannot cut double-stranded DNA, but retains the ability to complex with guide molecules and bind to target DNA sequences. Targeting specificity is determined by the base pairing of the Cas12 protein bound to the PAM sequence and the guide molecule that is complementary to the genomic locus. In some embodiments of the present disclosure, the dCas12 protein is a dCas12a protein.
[0115] Some Cas12 protein subtypes lack nuclease activity, which is due to the inactivation of the RuvC-like nuclease domain, or due to the loss of some or all of the RuvC-like nuclease domain. In contrast, one such subtype, VK type and related protein Cas12k, is associated with Tn7-like transposable elements tnsB, tnsC, and tniQ. See, for example, Strecker et al. (Science, 2019, 364(6448): 48-53). Cas12k retains the ability to complex with guide molecules and bind to target DNA sequences, and related Tn7-like proteins promote the transposition of RNA-guided DNA sequences. In some embodiments of the present disclosure, the Cas12 chRDNA guide / nucleoprotein complex is a Cas12k chRDNA guide / nucleoprotein complex.
[0116] Other amino acid changes may include glycosylated forms of the amino acid, aggregate conjugates with other molecules, and covalent conjugates with unrelated chemical moieties (e.g., pegylated molecules). Covalent variants may be prepared by attaching functions to groups found in the amino acid chain or at the N-terminal or C-terminal residues. In some cases, the mutated site-directed polypeptide may also include allelic variants and species variants.
[0117] In certain embodiments, Cas12 protein can be a fusion or chimeric protein comprising a first domain from Cas12 protein and a second domain from a different protein (such as Csy4 protein). The fusion modification of Cas12 protein can confer additional activity to the modified Cas12 protein. Such activities can comprise nuclease activity, methyltransferase activity, demethylase activity, DNA repair activity, DNA damage activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer formation activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity, glycosidase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, reverse transcriptase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity and / or myristoylation activity or demyristoylation activity that modifies a polypeptide associated with a nucleic acid target sequence (e.g., a histone).
[0118] In certain embodiments, the Cas12 protein may include one or more NLS sequences (e.g., attached to and / or inserted into the Cas12 protein sequence). The NLS sequence may be located, for example, at the N-terminus, the C-terminus, or inside the Cas12 protein (e.g., Cas12a protein), including combinations thereof (e.g., one or more NLSs are located at the N-terminus and one or more NLSs are located at the C-terminus). The NLS sequence may be derived from SV40 large T antigen, nucleoplasmin, 53BP1, VACM-1 / CUL5, CXCR4, VP1, ING4, IER5, ERK5, UL79, EWS, Hrp1, cMyc (1), cMyc (2), mouse c-able IV, Matα2, and MINIYO.
[0119] The NLS sequence can be covalently linked directly or through a linker polypeptide (e.g., to a Cas12 protein, to another NLS sequence, or to a fusion peptide sequence connected to a Cas12 protein). The length of the linker sequence can be optimized according to the structural properties of a specific Cas12 protein (e.g., solvent accessibility at the end, whether there are other key functional peptide sequences at the end, etc.) to ensure that the NLS sequence can be used for homologous important protein binding and transport.
[0120] In some embodiments, the linker sequence comprises at least one glycine, serine and / or threonine residue. In some embodiments, the linker sequence comprises at least one glycine residue and at least one serine residue. In some embodiments, the linker sequence comprises multiple glycine residues and at least one serine residue. In some embodiments, the linker sequence consists of or includes a GS sequence.
[0121] Genome editing in cells using the Cas12-chRDNA guide nucleoprotein complex
[0122] The Cas12 chRDNA guide molecules, Cas12 proteins and Cas12-chRDNA guide nucleoprotein complexes disclosed herein can be delivered to cells in vitro, ex vivo or in vivo by a variety of methods known to those of ordinary skill in the art. Non-limiting methods for introducing these components into cells include viral vector delivery, sonoporation, cell squeezing, electroporation, nuclear transfection, lipofection, particle gun technology, microprojectile bombardment or chemicals (e.g., cell penetrating peptides).
[0123] In some embodiments, electroporation can be used to deliver the Cas12 chRDNA guide molecule disclosed herein to cells. Electroporation can also be used to deliver the Cas12 chRDNA guide / nucleoprotein complex disclosed herein. In these methods, the chRDNA guide molecule or the Cas12 chRDNA guide / nucleoprotein complex is mixed with the target cell in an electroporation buffer to form a suspension. Then, this suspension is subjected to an electric pulse at an optimized voltage, which creates temporary holes in the phospholipid bilayer of the cell membrane, allowing charged molecules (such as nucleic acids and proteins) to pass through the holes and enter the cell. Reagents and equipment for electroporation are commercially available.
[0124] In some embodiments, the delivery of Cas12 chRDNA guide, Cas12 protein and Cas12-chRDNA guide nucleoprotein complex is achieved by packaging the components into compartments. The compartments including these components can be used in vivo (e.g., in cells of living organisms, provided that, in some embodiments, the organism is a non-human organism). In some embodiments, the compartments are biological compartments such as viruses (slow viruses, adenoviruses) or liposomes. In some embodiments, the compartments are non-biological compartments selected from the following: nanospheres, liposomes, quantum dots, nanoparticles, microparticles, nanocapsules, vesicles, polyethylene glycol particles, hydrogels and micelles.
[0125] In some embodiments, the compartment is a lipid nanoparticle (LNP).
[0126] When the Cas12 chRDNA guide molecule can be introduced into a cell having a Cas12 protein, thereby forming a Cas12-chRDNA guide nucleoprotein complex, the Cas12-chRDNA guide nucleoprotein complex can be used to cut a target nucleic acid or bind to it. The nucleoprotein complex can hybridize with a target nucleic acid including a PAM. The nucleoprotein complex includes a Cas12 chRDNA guide having a targeting region complementary to a nucleic acid target sequence. Optionally, a second Cas12-chRDNA guide nucleoprotein complex includes a Cas12 chRDNA guide having a second targeting region complementary to a second nucleic acid target, which is also introduced into the cell.
[0127] The step of binding to a nucleic acid target sequence can be performed in vitro (e.g., in a biochemical reaction or cultured cells), in vivo (e.g., in cells of a living organism or patient), or ex vivo (e.g., cells removed from a subject or patient for return to the subject or patient).
[0128] In another embodiment, the Cas12 protein-chRDNA guide nucleoprotein complex can also be used to introduce the donor polynucleotide into the cell to promote at least a portion of the donor polynucleotide to be incorporated into the genomic DNA of the cell. Typically, the donor polynucleotide is brought very close to the fixed-point target nucleic acid break by combining the donor polynucleotide with the Cas12 protein (e.g., Cas12a) that produces a double-strand break. This proximity enhances the insertion of the donor polynucleotide into the site of the double-strand break (e.g., homologous recombination).
[0129] Therapeutic compositions, uses and methods
[0130] The Cas12 chRDNA guide molecules and Cas12-chRDNA guide nucleoprotein complexes disclosed herein can be used to generate modified cells for therapeutic purposes. As disclosed in sequence number PCT / US21 / 55394, the modified cells can be used for adoptive cell therapy, such as adoptive immunotherapy.
[0131] Lymphocytes can be isolated from a subject (such as a human subject) by techniques well known in the art, for example, from blood or from a solid tumor (such as in the case of TIL), or from a lymphoid organ (such as thymus, bone marrow, lymph nodes, and mucosa-associated lymphoid tissue). After separation, lymphocytes can be characterized in terms of specificity, frequency, and function, for example, by an ELISPOT assay that measures the frequency of T cell responses. Separated lymphocytes can optionally be activated using techniques well known in the art to promote proliferation and differentiation into specialized effector lymphocytes.
[0132] In some embodiments, the Cas12-chRDNA guide nucleoprotein complex disclosed herein can be used, for example, to modify isolated lymphocytes by inserting a gene encoding a chimeric antigen receptor (CAR). In some embodiments, the Cas12-chRDNA guide nucleoprotein complex is used to inactivate endogenous T cell receptors (eg, TRAC genes). The resulting lymphocytes form CAR-T cells or CAR-NK cells for adoptive immunotherapy.
[0133] Additionally, the Cas12-chRDNA nucleoprotein complex can be used to protect the survival of adoptive cells in the host. In some embodiments, the protective modification includes inactivating immune checkpoint proteins (such as PD-1 proteins encoded by the PDCD1 gene). Other immune checkpoint proteins that can be inactivated include cytotoxic T lymphocyte antigen 4 (CTLA-4, also known as CD152), LAG3 (also known as CD223), Tim3 (also known as HAVCR2), BTLA (also known as CD272), BY55 (also known as CD160), TIGIT (also known as IVSTM3), LAIR1 (also known as CD305), SIGLEC10, 2B4 (also known as CD244), PPP2CA, PPP2CB, PTPN6, PTPN22, CD96, CRTAM, SIGLEC7, SIGL EC9, TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7, FADD, FAS, TGFBRII, TGFRBRI, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1, IL10RA, IL10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT1, FOXP3, PRDM1, BATF, GUCY1A2, GUCY1A3, GUCY1B2 and GUCY1B3. In some embodiments, the Cas12-chRDNA guide nucleoprotein complex is used to inactivate one or more immune checkpoint molecules.
[0134] In some embodiments, the protective modification comprises inactivating beta-2 microglobulin (B2M), a component of MHC class I molecules present on nucleated cells. In some embodiments, the protective modification comprises inserting an HLA-E gene into the inactivated B2M locus.
[0135] In some embodiments, the present invention is a method of treating or ameliorating a disease or condition by administering a cell modified with a V-type CRISPR system comprising a chRDNA disclosed herein. Table 3 lists the disease or condition and the gene to be targeted with a V-type CRISPR system comprising a chRDNA.
[0136] Table 3: Diseases and conditions and genes targeted by Type V CRISPR-chRDNA technology
[0137]
[0138]
[0139] Table 4: iPSC technology
[0140] Disease or condition Gene Target Cardiac fibrosis FAP (Fibroblast Activation Protein alpha) Spinocerebellar ataxia type 1 ATXN1 Spinal muscular atrophy (SMA) SMN1
[0141] Table 5: Cell therapies for cardiovascular and neurological diseases
[0142] Disease or condition Genetically modified cells Heart failure <![CDATA[HLA - CIITA - Cardiomyocytes]]> Obstructive Hypertrophic Cardiomyopathy (oHCM) <![CDATA[HLA - CIITA - Cardiac myosin - Cardiomyocytes]]> Amyotrophic lateral sclerosis (ALS) <![CDATA[HLA - CIITA - Motor Neuron]]> Spinal cord injury <![CDATA[HLA - CIITA - Neuron]]> Spinal muscular atrophy (SMA) <![CDATA[HLA - CIITA - Neuron]]> Spinal cord injury <![CDATA[HLA - CIITA - Neuron]]>
[0143] Table 6: Xenograft
[0144]
[0145] In some embodiments, a V-type CRISPR system comprising chRDNA produces a genome modification resulting in expression or elimination of one or more genes listed in Table 3 in the modified cell. In some embodiments, aberrant expression of a gene causes a disease or condition listed in Table 3, and elimination or expression of the gene resulting from the genome modification alleviates the disease or condition.
[0146] In some embodiments, the exogenous nucleic acid is inserted into the genome of the cell. Fig.10 and Fig.12 ), a donor polynucleotide comprising one or more copies of an exogenous gene is provided. The exogenous gene comprises a sequence encoding a protein under the control of a promoter of the gene, another promoter active in the target cell, or a constitutive promoter. The exogenous gene is selected from the list provided in Table 3.
[0147] In some embodiments, in the case of heart failure, spinal cord injury, SMA and ALS, the V-type CRISPR system including chRDNA will produce genomic modifications that eliminate gene expression that leads to graft rejection. This genomic modification enables the implantation of exogenous neurons (in the case of spinal cord injury, SMA or ALS) or exogenous cardiomyocytes (in the case of heart failure) without the recipient's immune system rejecting the exogenous neurons or cardiomyocytes. In some embodiments, the present invention is a method for treating a disease or condition of the central nervous system (CNS), the method comprising genetic modification achieved by a V-type CRISPR system, the system comprising causing HLA - / CIITA -In some embodiments, the present invention is a method for treating heart failure, the method comprising gene modification achieved by a V-type CRISPR system, the system comprising causing HLA - / CIITA - In some embodiments, the type V CRISPR system comprising chRDNA inactivates one or more of the MHC class I genes selected from HLA-A, HLA-A2, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G, and further inactivates the class II transactivator (CIITA) gene.
[0148] Lipid Nanoparticles (LNP)
[0149] In some embodiments, components of the V-type CRISPR system including chRDNA are encapsulated in microscopic lipid droplets sometimes referred to as lipid nanoparticles (LNPs). Examples of LNPs are described, for example, in Sharma et al. (2014), Next-generation delivery systems for proteins and genes for therapeutic purposes: why and how? (Next generation delivery system for proteins and genes of therapeutic purpose: why and how?) "Biomed Res Int". 2014: 327950, and further described in U.S. Patent Application Publication No. US20190136231, Lipid nanoparticle formulations for CRISPR / Cas components; No. US20160317676, Methods and compositions for delivery of nucleic acids; No. US20190022247, Lipids and lipidnanoparticle compositions for delivery of nucleic acids; and No. US20210251898, Lipid nanoparticles for mRNA vaccines.
[0150] In some embodiments, the diameter of the LNP used herein is between about 100 nm and about 1 μm, preferably <100 nm. In some embodiments, the LNP comprises one or more cationic lipids. The cationic lipids can be selected so that when combined, the combined pK a The measured value is not less than 6.1 and not more than 6.7, for example, between 6.2 and 6.6; or between 6.3 and 6.5. Cationic lipids can have a head group, one or more hydrophobic tails and a joint between the head group and the one or more tails. The head group can include an amine as a positively charged site. The amine can be a primary amine, a secondary amine, a tertiary amine or a quaternary amine. The one or more hydrophobic tails can include two hydrophobic chains that can be the same or different. The tail can be a fatty chain, a fatty acid chain or other hydrophobic chain. The joint can include, for example, a glyceride joint, an acyclic glyceride analog joint or a cyclic joint. The joint can include a functional group such as an ether, an ester, a phosphate, a phosphonate, a thiophosphate, a sulfonate, a disulfide, an acetal, a ketal, an imine, a hydrazone or an oxime. Cationic lipids include one or more amine groups that carry a positive charge. Preferred cationic lipids are ionizable so that they can exist in a positively charged or neutral form depending on pH. Ionization of cationic lipids affects the surface charge of lipid nanoparticles (LNPs) and may affect plasma protein absorption, blood clearance, tissue distribution, and the ability to fuse with cell membranes.
[0151] In some embodiments, LNP further includes a neutral lipid. The neutral lipid may be selected from DSPC, DPPC, POPC, DOPE or SM. The lipid capable of reducing aggregation may be a PEG lipid. In some embodiments, the lipid particles further include sterols. In some embodiments, the molar ratio of all cationic lipids in the particles is about 20% to about 60%; the neutral lipid may be present in a molar ratio of about 5% to about 25%; the sterol may be present in a molar ratio of about 25% to about 55%; and the PEG lipid may be PEG-DMA, PEG-DMG or a combination thereof, and may be present in a molar ratio of about 0.5% to about 15%.
[0152] Other examples of lipids for producing LNPs include DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE and GL67A-DOPE-DMPE-polyethylene glycol (PEG). The example of cationic lipids includes 98N12-5, C12-200, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1 and 7C1. Other examples of PEG-modified lipids include PEG-CerC14 and PEG-CerC20.
[0153] In some embodiments, the LNP further comprises a lipid capable of reducing aggregation (eg, aggregation of the LNP).
[0154] In some embodiments, the surface of the LNP is further modified with a polymer or lipid (e.g., chitosan, a cationic polymer or a cationic lipid), or coupled to a targeting molecule (an antibody specific for a cell surface receptor or a natural ligand of a cell surface receptor) to direct the nanoparticle to the appropriate cell type and increase the likelihood of cellular uptake, as described, for example, in Jian et al. (2012) Cationic core shell lipid nanoparticles for ocular gene delivery, Biomaterials 33(30):7621-30.
[0155] Delivery of LNPs
[0156] In some embodiments, the present invention includes delivering the V-type CRISPR system including the chRDNA described herein to the cells and tissues of the patient. In some embodiments, the delivery is carried out by lipid nanoparticles (LNP) described herein. Delivery can be completed in vitro, in vitro or in vivo to the patient's cells. In some embodiments, the LNP of the V-type CRISPR system including chRDNA is administered to the patient systemically (i.e., intravenously administered to the systemic circulation). In some embodiments, the target nucleic acid is expressed (or abnormally expressed) in a specific organ, and the LNP including the V-type CRISPR system including chRDNA is administered to this organ. In some embodiments, the LNP including the V-type CRISPR system including chRDNA is contacted with the patient's cells in vitro, and the treated cells are administered to the patient.
[0157] In some embodiments, the target nucleic acid is expressed (or aberrantly expressed) in the liver. In such embodiments, LNPs comprising a V-type CRISPR system comprising chRDNA are administered systemically or are administered into the hepatic circulation (e.g., the portal vein or another hepatic blood vessel or a liver-associated blood vessel).
[0158] In some embodiments, the target nucleic acid is expressed (or aberrantly expressed) in the liver, and more specifically in hepatocytes. In such embodiments, the patient's own (autologous) hepatocytes or donor (allogeneic) hepatocytes are treated ex vivo using LNPs comprising a V-type CRISPR system comprising chRDNA, and the treated hepatocytes are administered systemically to the patient or to the hepatic circulation (e.g., the patient's portal vein or another hepatic blood vessel or liver-associated blood vessel).
[0159] In some embodiments, the target nucleic acid is expressed (or aberrantly expressed) in hepatic sinusoidal endothelial cells of the liver or in hematopoietic cells throughout the body (e.g., the Factor VIII gene, deficiency of which is the cause of hemophilia A). In such embodiments, the target cells for in vivo or ex vivo administration of a Type V CRISPR system comprising chRDNA comprise hepatic sinusoidal endothelial cells, progenitor cells that differentiate into hepatic sinusoidal endothelial cells, hematopoietic endothelial cells, or progenitor cells that differentiate into hematopoietic endothelial cells.
[0160] In some embodiments, the target nucleic acid is expressed (or abnormally expressed) in cells of the eye. In some embodiments, LNPs comprising a V-type CRISPR system comprising chRDNA are delivered to the eye (intraocular delivery). In some embodiments, the delivery is intravitreal. In some embodiments, the delivery is directed to the retina to reach the retinal pigment epithelium.
[0161] In some embodiments, administration is in combination with a pharmaceutically acceptable carrier.
[0162] Induced Pluripotent Stem Cells (iPSCs)
[0163] In some embodiments, the present invention includes a method of ex vivo cell-based therapy, the method comprising editing the genome of induced pluripotent stem cells (iPSCs) using a type V CRISPR system comprising chRDNA; differentiating the edited iPSCs into cells of a desired lineage, and implanting the differentiated cells into a patient.
[0164] In some embodiments, iPSCs are patient-derived (autologous). In some embodiments, somatic cells are obtained from a subject or patient, reprogrammed into induced pluripotent stem cells (iPSCs), the genome is edited using a V-type CRISPR system including chRDNA as described herein, redifferentiated into cells of the desired cell type, and administered to the same subject or patient.
[0165] In some embodiments, the iPSCs are donor-derived or cell line-derived. In some embodiments, the differentiation of the iPSCs is artificially induced in vitro or ex vivo by administering certain stimuli.
[0166] Reprogramming cells into iPSCs
[0167] In some embodiments, the differentiated cells are reprogrammed into iPSC by applying external agents in vitro or in vitro artificial induction. In some embodiments, the differentiated cells are reprogrammed into iPSC including reversing one or more heritable nucleic acid modification patterns, such as methylation. In some embodiments, the differentiated cells are reprogrammed into iPSC by expressing certain genes in differentiated cells to achieve. In some embodiments, plasmid or viral expression vectors are used to introduce genes into cells. In some embodiments, genes are introduced as mRNA that can be translated in cells. In some embodiments, the genes induced to be reprogrammed are one or more of Oct4, Sox2, Klf4 and c-Myc, such as Takahashi et al., (2006) defined factors induce pluripotent stem cells from mouse embryonic and adult fibroblast cultures (Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors), "Cell" 126 (4): described in 663-76. In some embodiments, the gene that induces reprogramming is one or more or all three of Oct4, Sox2 and NANOG, as described in Budniatzky et al. (2014) Concise review: reprogramming strategies for cardiovascular regenerative medicine: from induced pluripotent stem cells to direct reprogramming, Stem Cells Transl Med. 3(4): 448-57 and references cited therein. In some embodiments, the gene that induces reprogramming is one or more of the following: Sox1, Sox3, Sox15, Sox18, Klf1, Klf2, Klf5, NR5A2, c-Myc, l-Myc, n-Myc, Rem2, Tert and LIN28 or Wnt.In some embodiments, reprogramming of somatic cells to iPSCs is enhanced by introducing one or more of the following: MEK inhibitors, DNA methyltransferase inhibitors, histone deacetylase (HDAC) inhibitors, valproic acid, 5'-azacytidine, dexamethasone, suberoylanilide hydroxamic acid (SAHA), vitamin C and trichostatin (TSA), suberoylanilide hydroxamic acid (SAHA (e.g., MK0683, vorinostat) and other hydroxamic acids), BML-210, Depudecin (e.g., (-)-Depudecin), HC toxin, Nullscript (4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxybutyramide), phenylbutyrate (e.g., sodium phenylbutyrate), and valproic acid ((VP A) and other short-chain fatty acids), Scritex, suramin sodium, trichostatin A (TSA), APHA compound 8, aphidicolin, sodium butyrate, pivaloyloxymethylbutyrate (Pivanex, AN-9), Triproxin B, Chlamydocin, depsipeptide (also known as FR901228 or FK228), benzamides (e.g., CI-994 (e.g., N-acetyl pyridamole) and MS-27-275), MGC D0103, NVP-LAQ-824, CBHA (m-carboxycinnamic acid dihydroxamic acid), JNJ16241199, Tubacin, A-161906, proxamide, oxamflatin, 3-C1-UCHA (e.g., 6-(3-chlorophenylureido)hexanehydroxamic acid), AOE (2-amino-8-oxo-9,10-epoxydecanoic acid), CHAP31 and CHAP50.
[0168] In some embodiments, the reprogramming of differentiated cells into iPSCs is assessed by detecting or measuring the expression of markers associated with iPSCs. In some embodiments, reprogramming is assessed by detecting or measuring the expression of one or more genes selected from the following: SSEA3, SSEA4, CD9, Nanog, Fbx15, Ecat1, Esg1, Eras, Gdf3, Fgf4, Cripto, Dax1, Zpf296, Slc2a3, Rex1, Utf1, and Nat1. In some embodiments, reprogramming into motor neurons is assessed by detecting or measuring the expression of a combination of Sox1, Pax6, nestin, HB9, MAP2, neurofilaments, Tuj1, and Olig2. In some embodiments, expression is assessed or measured by Southern blotting or PCR (including reverse transcription PCR (RT-PCR), real-time PCR (rtPCR), and digital droplet PCR (ddPCR)) or nucleic acid sequencing to detect the mRNA in question. In some embodiments, expression is confirmed by detecting the protein in question by an immunological method selected from the group consisting of Western blot, flow cytometry, immunochemistry, and immunocytochemistry.
[0169] Modification of iPSCs
[0170] In some embodiments, the present invention includes a method of genetically modifying iPSCs to achieve expression of a gene, wherein the abnormal expression of the gene is associated with a disease or condition in the patient. The genetically modified iPSCs are then differentiated into a cell type characterized by the abnormal expression of the gene in the patient, and the differentiated cells are administered to the patient to alleviate the symptoms of the disease or condition.
[0171] In some embodiments, iPSCs are cultured in a suitable medium (e.g., mTeSR-plus medium (STEMCELL Technologies, Cambridge, Mass.)) containing one or more supplements prior to nucleofection with a V-type CRISPR system comprising chRDNA. In some embodiments, cells are dispersed with accutase (STEMCELL Technologies, Cambridge, Mass.) prior to nucleofection. In some embodiments, cells are counted to achieve a desired number of cells in the nucleofection well. In some embodiments, 4 x 10 3 -2x 10 4 Cells were present in wells of a 96-well plate. Cas12a guide / nucleoprotein complexes were added and nucleofection was performed according to the manufacturer's recommendations. In some embodiments, Nucleocuvette TM Plate and Nucleofector TMInstrument (Lonza, Allendale, NJ).
[0172] Differentiation of iPSCs
[0173] In some embodiments, the method includes a step of differentiating the genetically modified iPSC using a V-type CRISPR system including chRDNA according to the method of the present invention. In some embodiments, the iPSC is differentiated into cells of the central nervous system (CNS) (such as neurons, including motor neurons), retinal cells or glial cells, cells of the cardiovascular system (such as endothelial cells or cardiomyocytes). In some embodiments, the iPSC is differentiated into hepatocytes or mesenchymal stem cells. In some embodiments, the iPSC is differentiated into eyeglass (non-neural) cells, such as corneal cells, scleral cells or choroidal cells.
[0174] In some embodiments, iPSC is differentiated into neurons. In some embodiments, the method comprises preparing a fresh culture of the confluent iPSC and dissociating the confluent culture of the iPSC before placing it in a neural induction medium, wherein the neural induction medium includes one or more of the following: serum replacement, non-essential amino acids, glutamine or glutamine substitutes, vitamins, GSK-3 inhibitors, TGF-β receptors or TGF-β inhibitors, ALK inhibitors, doxorubicin and compound E. In some embodiments, one or more culture medium exchanges are performed. In some embodiments, the subsequent culture medium includes growth factors such as FGF and EGF. In some embodiments, for the differentiation and generation of motor neurons, the subsequent culture medium is MN induction culture medium and neural basal culture medium. In some embodiments, the culture medium is further supplemented with one or more of the following: all-trans retinoic acid, sonic hedgehog protein, purmorphamine, SAG dihydrochloride, CNTF and GDNF. In some embodiments, in order to assess differentiation into neurons, cells are assessed by fluorescence microscopy. In some embodiments, cells are fixed in formaldehyde or paraformaldehyde, permeabilized with Triton-X and / or Tween-20, and stained with primary antibodies that specifically bind to one or more of Sox1, Pax6, nestin, HB9, MAP2, neurofilaments, Tuj1, and Olig2. To further assess differentiation into motor neurons, calcium activity is assessed, for example, by imaging with Oregon Green 488BAPTA-2 calcium indicator. In some embodiments, for example, the electrical activity of cells is measured using a MultiClamp 700B microelectrode amplifier (Molecular Devices, San Jose, Cal., San Jose, Cal.).
[0175] In some embodiments, iPSC is differentiated into myocytes, such as cardiomyocytes. In some embodiments, iPSC is freshly grown to achieve a culture confluence of 60%-70%, and treated with one or more of a GSK-3 inhibitor and a Wnt-dependent phosphorylation blocker, and incubated in a medium containing insulin. In some embodiments, cells are assessed by measuring gene expression of cardiomyocyte-specific markers (e.g., TBX5, TNNT2, MYH6, and MYL7) and optionally expression of pluripotency markers (NANOG, POUF5F1).
[0176] Xenotransplantation
[0177] In some embodiments, the present invention is a method of preparing a transgenic non-human mammal for xenotransplantation by modifying the genome of an animal using a type V CRISPR system including chRDNA to eliminate the expression of one or more genes that produce immune incompatibility and / or introduce one or more genes that establish immune compatibility between a non-human donor and a human recipient or reduce the likelihood of rejection by the human immune system.
[0178] In some embodiments, the transgenic non-human mammal is a pig, and the method comprises delivering a type V CRISPR system comprising chRDNA into a pig oocyte, egg, or fertilized egg, followed by transferring the genetically modified oocyte, egg, or fertilized egg to a foster female.
[0179] In some embodiments, the transgenic non-human mammal is a pig, and the method comprises delivering a type V CRISPR system comprising chRDNA into a pig somatic cell, and further comprises transferring the nucleus of the somatic cell into an enucleated egg or fertilized egg, and subsequently transferring the resulting egg or fertilized egg to a foster female.
[0180] In some embodiments, the genomic modification is the insertion of a functional copy of a gene that causes the production of an exogenous protein. In some embodiments, the exogenous protein has cytoprotective properties, anticoagulant properties, complement inhibitor properties or immunosuppressive properties. In some embodiments, the exogenous gene is a human gene. In some embodiments, the exogenous protein has cytoprotective properties, and the gene is selected from A20, HO-1, FAT-1 and TNF-α receptors. In some embodiments, the exogenous protein has anticoagulant properties, and the gene is selected from CD39, hirudin, TFPI, EPCR and TBM. In some embodiments, the exogenous protein has complement inhibitor properties, and the gene is selected from CD46, DAF (CD55), CD59 and CR1. In some embodiments, the exogenous protein has immunosuppressive properties, and the gene is selected from CTLA4 and CD47.
[0181] In some embodiments, the genomic modification is a disruption of an endogenous gene that results in reduced or eliminated expression of an endogenous protein. In some embodiments, the disrupted endogenous gene is part of the porcine major histocompatibility complex (SLA complex) and is selected from SLA-1, SLA-2, SLA-3, SLA-6, SLA-7, SLA-8, SLA-9, SLA-11, and SLA-12. In some embodiments, the disruption of one or more of the porcine class I SLA genes is accompanied by the insertion of one or more of the human class I HLA genes selected from HLA-A, HLA-A2, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G.
[0182] In some embodiments, the disrupted endogenous gene is one or both of α(1,3)-galactosyltransferase (GT) and monophosphate cytidine-N-acetylneuraminic acid hydroxylase (CMAH). Reducing or eliminating the expression of GT and CMAH reduces the immunogenicity of porcine xenotransplantation by disrupting the glycosylation of surface proteins in porcine cells. GT catalyzes the addition of galactose-α-1,3-galactose residues to glycoproteins. CMAH catalyzes the conversion of N-acetylneuraminic acid (Neu5Ac) to N-glycolylneuraminic acid (Neu5Gc), which, with the participation of other porcine enzymes, forms an immunogenic glycoprotein found on the surface of porcine cells but not found in human cells.
[0183] Examples
[0184] Example 1. Cloning, expression, production and assembly of Cas12a-guide nucleoprotein complex
[0185] A non-limiting example of the successful preparation of a functional Cas12a-guide nucleoprotein complex is described in International Patent Application No. PCT / US2021 / 055394 filed on October 18, 2021.
[0186] In short, the aminoacid coccus (strain BV3L6) catalytic activity Cas12a protein (AsCas12a) sequence can be codon optimized to be expressed in Escherichia coli (E.coli) cells and conjugated to a nuclear localization sequence (NLS) by a linker (e.g., a glycine-serine linker). Several NLS sequences of Cas12a have been verified, including nucleoplasmin (NLP) NLS and SV40 large T antigen NLS. The DNA sequence encoding NLS-Cas9 can be cloned into a suitable bacterial expression vector using standard cloning methods.
[0187] The AsCas12a protein can be expressed in E. coli using an expression vector and purified using affinity chromatography, ion exchange, and size exclusion chromatography, essentially as described in, for example, Swarts et al. (Molecular Cell, 2017, 66: 221-233).
[0188] Cas12a guides can be generated by connecting the targeting region to a specific Cas12a guide activation region. The targeting region or spacer preferably includes a 20-nucleotide target binding sequence. The target binding sequence is complementary to the target sequence occurring downstream (in the 3' direction) of 5'-TTTV or 5'-TTTN PAM. Cas12a guides (such as crRNAs and chRDNA) can be synthesized by commercial manufacturers or produced by in vitro transcription (e.g., T7 fast high-yield RNA synthesis kit; New England Biolabs, Ipswich, Mass., Ipswich, Mass.).
[0189] For example, a nucleoprotein complex can be formed at a concentration of 80 pmol Cas12a protein: 240 pmol guide. Each of the Cas12a protein and the guide component (e.g., crRNA or chRDNA) can be adjusted to the desired total concentration, incubated at 95 ° C for 2 minutes, taken out from a thermal cycler, and balanced to room temperature. The Cas12a protein is diluted to an appropriate concentration in a binding buffer (60 mM TRIS-acetate, 150 mM potassium acetate, 30 mM magnesium acetate, pH 7.9), and the final volume is 1.5 μl, and mixed with 1 μl of the guide component, and then incubated at 37 ° C for 10 minutes.
[0190] Example 2. Tiled target genes for Cas12a cleavage
[0191] To target a selected gene, all 20-nucleotide sequences (in the 3' direction) located downstream of a PAM motif (e.g., 5'-TTTV) can be used for targeting. Target selection criteria include, but are not limited to, homology to other regions in the genome; percentage GC content; melting temperature; and the presence of homopolymers within the spacer.
[0192] The identified 20-nucleotide sequence can be appended downstream (in the 3' direction) to the AsCas12a guide activation region sequence and thereby produce the desired guide.
[0193] Optionally, the guide can be designed to contain one or more deoxyribonucleotides (DNA) within the ribonucleotides (RNA) in the targeting region or activation region.
[0194] Further optionally, the guide can be designed to include one or more chemically modified nucleotides. Chemical modifications can include backbone modifications, nitrogenous base modifications, and sugar modifications. An example is phosphorothioate modification of the nucleic acid backbone.
[0195] Example 3. (Predictive) Transfection of human induced pluripotent stem cells using Cas12a-chRDNA nucleoprotein complex.
[0196] This example describes the use of Cas12a guide / nucleoprotein complexes to perform nuclear transfection on iPSCs. Cas12a (AsCas12a) was prepared as described herein. Guides were prepared for target sequences of the genes listed in Table 3.
[0197] Cells were prepared as follows. Prior to transfection, iPSCs were cultured in mTeSR-plus medium (Stem Cell Technologies, Cambridge, Mass.) supplemented with a Rho-associated coiled-coil protein kinase inhibitor ("ROCKi", MilliporeSigma, Burlington, Mass.) at a final concentration of 10uM at 37°C for 3 hours. The mTeSR-plus / ROCKi medium was removed, and the iPSCs were washed with 10mL PBS, followed by 3mL of accutase (Stem Cell Technologies, Cambridge, Mass.), and the cells were incubated at 37°C for 5-10 minutes. Then, 7mL of mTeSR-pulse and ROCKi were added to the cells, and the cells were mixed and counted. The cells were then centrifuged, the culture medium was removed, and the cells were washed with 10mL PBS, centrifuged again and the PBS was removed. The cells were resuspended in a Nucleofector TM P4 or P3 (Lonza, Allendale, NJ) solution at a density of 2 x 10 per sample. 5 -10 6 Then, 20 μl of cell suspension was added to each well containing 2.5 μl of Cas12a guide / nucleoprotein complex and the entire volume of each well was transferred to a 96-well Nucleocuvette TM Plates (Lonza, Allendale, NJ). The plates were loaded into the Nucleofector TM 96-well shuttle and using CA137 Nucleofector TMProcedure for nucleofection of cells. After nucleofection, add 77.5 μl of ImmunoCult-XF complete medium supplemented with IL-2 (100 units / mL) to each well and transfer the entire volume of the transfected cell suspension to a 96-well cell culture plate containing 100 μl of pre-warmed ImmunoCult XF complete medium supplemented with IL-2 (100 units / mL). Prior to downstream analysis, transfer the plate to a tissue culture incubator and maintain at 37°C in 5% CO2 for 48 hours.
[0198] Example 4. (Predictive) Differentiation of Nucleofected iPSCs into Motor Neurons
[0199] This example describes the differentiation of iPSCs into motor neurons after nuclear transfection. In short, the protocol from Bianchi, F. et al. ((2018) Rapid and efficient differentiation of functional motor neurons from iPSC for neural injury, Stem Cell Research 32:126) was used. After nuclear transfection, the iPSCs were allowed to rest and grow to confluence. The confluent iPSCs were dissociated using accutase and plated in neural induction medium (NIM) at 0.5x10 6Cells / well were placed on MG-coated 6-well plates in NIM consisting of a 1:1 mixture of KO-DMEM / F:12 and neural basal medium (NBM), supplemented with 10% KnockOut Serum Replacement, 1% non-essential amino acids (NEAA) (both from ThermoFisher Scientific), and 1% GlutaMAX, 0.1 mM L-ascorbic acid, 3 μM CHIR99021 (both from Sigma-Aldrich), 2 μM SB431542 (CellGuidance Systems), 1 μM doxormorphine, and 1 μM Compound E (both from StemCell). 1% RevitaCell (ThermoFisher Scientific) was added only in the first 24 hours. NIM was changed daily for six days, after which cells were dissociated with accutase and plated in NPC expansion medium consisting of a 1:1 mixture of KO-DMEM:F12 and NBM supplemented with 1% P / S, 1% B27, 1% N2, 1% NEAA, 1% GlutaMAX, 0.1 mM L-AA, 10 ng / mL bFGF, and 10 ng / mL EGF. Optionally, one fifth of the cells were retained at each passage for marker analysis.
[0200] For differentiation and generation of motor neurons, NPCs were cultured for 6 days in MN induction medium consisting of a 1:1 mixture of KO-DMEM:F12 and Neurobasal medium supplemented with 1% P / S, 1% B27, 1% N2, 1% non-essential amino acids, 1% GlutaMAX, 0.1 mM L-ascorbic acid, 10 μM all-trans retinoic acid, 100 ng / ml recombinant SHH, 1 μM purmorphamine (Abcam), and 1 mM SAG dihydrochloride (Sigma-Aldrich). Seven days later, cells were dissociated using accutase and replated in maturation medium consisting of 1:1 KO-DMEM:F12 and NBM supplemented with 1% P / S, 1% B27, 1% N2, 1% NEAA, 1% GlutaMAX, 0.1 mM L-AA, 10 ng / mL CNTF, 10 ng / ml BDNF, 10 ng / mL NT-3, and 10 ng / mL GDNF.
[0201] Cell analysis
[0202] To assess differentiation, cells were fixed in phosphate buffered saline (PBS) solution containing 3.75% paraformaldehyde, blocked and permeabilized with 0.1% Triton-X, 0.1% Tween-20 and PBS containing 2.5% BSA. Primary antibodies (e.g., from Abcam) were added for Sox1, Pax6, nestin, HB9, MAP2, neurofilaments, Tuj1, and Olig2. Next, cells were counterstained with secondary antibodies labeled with AlexaFluor. For example, the nuclei were labeled with NucBlue. Cells were imaged using a fluorescence microscope (e.g., an inverted fluorescence microscope).
[0203] In order to further assess differentiation into motor neurons, calcium activity was imaged using Oregon Green 488BAPTA-2 calcium indicator. Cells were incubated for 30 minutes in an imaging medium (e.g., FluoroBrite-DMEM imaging medium) containing a dye solution, washed twice in PBS, and further incubated for 30 minutes in fresh FBDMEM. Standard FITC filters were used to image cells, and the fluorescence intensity of single segmented cells was recorded in time. In order to further assess differentiation into motor neurons, the electrical activity of cells was measured using MultiClamp 700B microelectrode amplifier (Molecular Devices, San Jose, California).
[0204] Example 5. (Prophetic) Differentiation of nucleofected iPSCs into cardiomyocytes.
[0205] This example describes the differentiation of iPSCs into cardiomyocytes by nuclear transfection. In short, the protocol from Balafkan, N. et al. ((2020) A method for differentiating human induced pluripotent stem cells toward functional cardiomyocytes in 96-well microplates, Nature 10: 18498) was used. After nuclear transfection, iPSCs were allowed to stand and grow to confluence. High-grade DMEM / F-12 and Geltrex (both from Thermo Fisher Scientific) were used to coat the wells in 96-well plates. Before plating, human iPSC colonies were converted into uniform cell suspensions and cultured at 2.4 x 10 4 cells / cm 2The density of 500 μM Wnt-dependent phosphorylation blockers (e.g., IWP2) was used to process cells, and incubated for another 48 hours (the 3rd day to the 4th day). On the 5th day, the culture medium was changed to contain no Wnt-P inhibitors, and cells were placed for 48 hours (the 5th day to the 6th day). On the 7th day, the culture medium was changed to contain insulin. Cells were assessed by measuring the gene expression of cardiomyocyte-specific markers (e.g., TBX5, TNNT2, MYH6 and MYL7), the expression of pluripotency markers (NANOG, POUF5F1) was reduced.
[0206] Example 6. Cultivation of immortalized mouse hepatocytes
[0207] This example illustrates the cultivation of the immortalized mouse hepatocyte cell line H2.35 (ATCC; Manassas, VA).
[0208] H2.35 cells were removed from liquid nitrogen storage and thawed in a 37°C water bath for 3 minutes. Cells were diluted into calcium- and magnesium-free phosphate-buffered saline (PBS; Thermo Scientific, Wilmington, DE) to a final volume of 10 mL and centrifuged at 300 g for 5 minutes. PBS was aspirated and cells were resuspended in 10 mL of prewarmed H2.35 medium consisting of Dulbecco's Modified Eagle Medium (DMEM; Thermo Scientific, Wilmington, DE) and 1 g / mL glucose, supplemented with 4% fetal bovine serum and 200 nM dexamethasone (Merck / Millipore-Sigma, Munich, Germany). Use The cells were counted using an automated cell counter (Life Technologies; Grand Island, NY). The cells were then plated in adherent flat-bottom flasks at 10,000 cells / cm 2 The cells were cultured at a density of 1.5 and incubated at 32°C in 10% CO2.
[0209] When confluence reached 60%-70%, cells were routinely passaged by aspirating the medium and washing with enough PBS to cover the bottom of the flask and gently rocking back and forth. Then, the PBS was aspirated and room temperature (RT) Accutase (Thermo Scientific, Wilmington, DE) was added to a sufficient volume to cover the bottom of the flask, and the flask was gently rocked back and forth and incubated at room temperature for 3 minutes. The flask was gently tapped five to ten times with the palm of the hand to loosen the cells, and 2.5 volumes of H2.35 medium relative to the volume of Accutase were added to the flask and mixed using a serological pipette. The cells were centrifuged at 300g for 5 minutes, the medium was decanted, and the flask was used. 3. Count with an automated cell counter and count cells at 10,000-20,000 cells / cm in H2.35 medium. 2 Inoculate new flasks at a density of 1.
[0210] Example 7. Cloning, expression, production and assembly of Cas12a guide / nucleoprotein complex
[0211] This example describes methods for cloning, expressing, and purifying Cas12a guide / nucleoprotein complexes, as well as methods for producing Cas12a guide components.
[0212] A. Cloning of Cas12 protein
[0213] The aminoacidococcus (strain BV3L6) catalytic activity Cas12a protein sequence (SEQ ID NO: 1) is codon optimized to be expressed in Escherichia coli cells. At the C-terminus, a glycine-serine linker and a nuclear localization sequence (NLS) (SEQ ID NO: 2) are added. The oligonucleotide sequence encoding Cas12a-NLS protein (referred to as AsCas12a and Cas12a protein in the following examples) is provided to commercial manufacturers for synthesis. Then, the DNA sequence is cloned into a suitable bacterial expression vector using standard cloning methods.
[0214] B. Expression and purification of Cas12a protein
[0215] The AsCas12a protein was expressed in E. coli using an expression vector and purified using affinity chromatography, ion exchange, and size exclusion chromatography, essentially as described in, for example, Swarts et al. (Molecular Cell, 2017, 66: 221-233).
[0216] C. Generation of Cas12a guide components
[0217] The Cas12a guide is generated by connecting the targeting region to a specific Cas12a guide activation region. The targeting region or spacer preferably includes a 20-nucleotide target binding sequence. The target binding sequence is complementary to the target sequence occurring downstream (in the 3' direction) of a 5'-TTTV or 5'-TTTN PAM. Exemplary Cas12a guide activation region sequences are SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 10 of aminoacidococcus, Lachnospiraceae bacteria (L.bacterium) and Francisella novo Cas12a species, respectively.
[0218] The Cas12a guide sequences (such as crRNA and chRDNA) were provided to commercial manufacturers for synthesis.
[0219] Guide RNA components (such as crRNA) can be produced by in vitro transcription (e.g., T7 Rapid High Yield RNA Synthesis Kit; New England Biolabs, Ipswich, MA) from double-stranded (ds) DNA templates by incorporating a T7 promoter at the 5' end of the dsDNA template sequence.
[0220] D. Assembly of the Cas12a guide / nucleoprotein complex
[0221] The amino acid coccus Cas12a (AsCas12a) marked with a C-terminal nuclear localization sequence is recombinantly expressed in Escherichia coli and purified using chromatography. Unless otherwise stated, the nucleoprotein complex is formed with a concentration of 80pmol Cas12a protein: 240pmol guide. Before assembling with the Cas12a protein, each of the guide components (e.g., crRNA or chRDNA) is adjusted to the desired total concentration (240pmol), and the final volume is 1 μl, incubated at 95°C for 2 minutes, taken out from a thermal cycler, and balanced to room temperature. The Cas12a protein is diluted to an appropriate concentration in a binding buffer (60mM TRIS-acetate, 150mM potassium acetate, 30mM magnesium acetate, pH 7.9), and the final volume is 1.5 μl, and mixed with 1 μl of the guide component, and then incubated at 37°C for 10 minutes. Use the Cas12a guide / nucleoprotein complex immediately, or freeze at -20°C until needed.
[0222] Example 8. Electroporation of immortalized mouse hepatocytes with Cas12a guide / nucleoprotein complexes.
[0223] This example illustrates electroporation of the immortalized mouse hepatocyte cell line H2.35 with a Cas12a guide / nucleoprotein complex for gene editing.
[0224] Using Nucleofector TMThe Cas12a guide / nucleoprotein complex of Example 7 was transfected into H2.35 using a 96-well Shuttle system (Lonza, Allendale, NJ). The Cas12a guide / nucleoprotein complex was dispensed into each well of a 96-well plate in a final volume of 2.5 μl. H2.35 cells were removed from the culture flask in a manner similar to that described in Example 1. After counting the H2.35, 100,000 cells were resuspended in 17.5 uL of CTS according to the transfection conditions. TM Xenon TM Electroporation buffer (Thermo Scientific, Wilmington, DE) was added and mixed with 2.5 uL of Cas12a guide / nucleoprotein complex and transferred to a 96-well Nucleocuvette TM Plates (Lonza, Allendale, NJ). The plates were loaded into the Nucleofector TM 96-well Shuttle (Lonza, Allendale, NJ) and using an EH-110 Nucleofector TM Cells were nucleofected using the ELISA procedure (Lonza, Allendale, NJ).
[0225] After nucleofection, add 80 μl of H2.35 medium to each well and transfer the entire volume of transfected cell suspension to a 96-well cell culture plate containing 100 μl pre-warmed H2.35 medium. Prior to downstream analysis, transfer the plate to a tissue culture incubator and maintain at 32°C in 10% CO2 for 72 hours.
[0226] Example 9. Tiling of mouse genes using Cas12a guide / nucleoprotein complexes
[0227] This example describes the design and use of Cas12a guide / nucleoprotein complexes to target genes encoding mouse proprotein convertase subtilisin / kexin type 9 (PCSK9), transthyretin (TTR), and angiopoietin-like 3 (ANGPTL3) in the immortalized mouse hepatocyte cell line H2.35.
[0228] A. Design of AsCas12a crRNA guide
[0229] A 20-nucleotide sequence located downstream (in the 3' direction) of the 5'-TTTV PAM motif in the coding region of the genes encoding mouse PCSK9, TTR, and ANGPLT3 was selected for targeting (SEQ ID NO: 5-94). Target selection criteria include, but are not limited to, homology to other regions in the genome; percentage GC content; melting temperature; and the presence of homopolymers within the spacer.
[0230] The identified 20-nucleotide sequence was appended downstream (in the 3' direction) of the AsCas12a activation region sequence (SEQ ID NO: 3).
[0231] The sequence was provided to a commercial manufacturer for synthesis. Then, a separate Cas12a guide / nucleoprotein complex was prepared as described in Example 7 and transfected into primary H2.35 cells as described in Example 3.
[0232] B. Determining Genome Editing Efficiency
[0233] (1) Generation of target dsDNA sequences for deep sequencing
[0234] 72 hours after transfection, 50 μL QuickExtract TM DNA extraction solution (Epicentre, Madison, WI) was used to isolate gDNA from nucleofected H2.35 cells, followed by incubation at 37°C for 10 minutes, 65°C for 30 minutes, and 95°C for 3 minutes to stop the reaction. The isolated gDNA was diluted with 50 μL of sterile water, and the samples were stored at -20°C.
[0235] Using isolated gDNA, the first PCR was performed at 1x concentration using Q5 hot start high fidelity 2X master mix (New England Biolabs, Ipswich, Massachusetts), using primers designed to amplify the region around the Cas12a target, 0.5 μM of each primer, and 3.75 μL of gDNA, with a final volume of 10 μL. Amplification was performed by the following steps: initial cycle at 98°C for 1 minute; 35 cycles, 10 seconds at 98°C, 20 seconds at 60°C, 30 seconds at 72°C; and final extension at 72°C for 2 minutes. The PCR reaction was diluted 1:100 in water.
[0236] A unique set of index primers for barcode PCR was used to facilitate multiplex sequencing of each sample. Barcode PCR was performed using a reaction mixture including 1x concentration of Q5 Hot Start High Fidelity 2X Master Mix (New England Biolabs, Ipswich, MA), 0.5 μM of each primer, and 1 μL of the first PCR diluted 1:100 in a final volume of 10 μL. The reaction mixture was amplified as follows: 1 min at 98°C; followed by 12 cycles of 10 sec at 98°C, 20 sec at 60°C, and 30 sec at 72°C; and a final extension reaction at 72°C for 2 min.
[0237] (2) SPRIselect cleaning
[0238] PCR reactions were pooled and transferred to a single microcentrifuge tube for SPRIselect (Beckman Coulter, Pasadena, CA) bead-based amplicon cleanup for sequencing.
[0239] Add 0.9 volumes of SPRIselect beads to the amplicon, mix, and incubate at room temperature for 10 minutes. Place the microcentrifuge tube on a magnetic tube rack until the solution is clear. Remove the supernatant and discard, wash the residual beads with 1 volume of 85% ethanol, and incubate the beads at room temperature for 30 seconds. After incubation, aspirate the ethanol and air dry the beads at room temperature for 10 minutes. Remove the microcentrifuge tube from the magnetic rack and add 0.25 volumes of Qiagen EB buffer (Qiagen, Venlo, Netherlands) to the beads, mix vigorously, and incubate at room temperature for 2 minutes. Place the microcentrifuge tube back on the magnet, incubate until the solution is clear, and dispense the supernatant containing the purified amplicon into a clean microcentrifuge tube. Use Nanodrop TM Purified amplicons were quantified using the Thermo Scientific 2000 System (Thermo Scientific, Wilmington, DE) and the Fragment Analyzer TM Library quality was analyzed using the ANALYTIC® system (Advanced Analytical Technologies, Ames, IA) and the DNF-910 dsDNA kit (Advanced Analytical Technologies, Ames, IA).
[0240] (3) Deep sequencing settings
[0241] As per Nanodrop TM Pooled amplicons were normalized to a concentration of 4 nM, calculated from the 2000 system value and the average size of the amplicons. Libraries were analyzed on a MiSeq sequencer (Illumina, San Diego, CA) using the MiSeq kit v2 (Illumina, San Diego, CA) for 300 cycles with two 151-cycle paired-end runs and two 8-cycle index reads.
[0242] (4) Deep sequencing data analysis
[0243] The identity of products in the sequencing data is determined based on the index barcode sequence that is aligned to the amplicon in the barcode-encoded PCR. Computational scripts are used to process MiSeq data, for example, to perform the following tasks:
[0244] a. Align the reads to the mouse genome (build GRCm38 / mm10) using Bowtie (bowtie-bio.sourceforge.net / index.shtml) software;
[0245] b. comparing the aligned reads to the expected wild-type genomic locus sequence and discarding reads that do not align to any part of the wild-type locus;
[0246] c. Aggregate the reads matching the wild-type sequence;
[0247] d. Classify and aggregate reads with indels (insertion or deletion of bases) by indel type; and
[0248] e. Divide the total indel reads by the sum of wild-type reads and indel reads to get the percentage of mutant reads.
[0249] By identifying the indel sequence of the region targeted by the Cas12a guide / nucleoprotein complex, the genome editing efficiency of the resulting Cas12a guide / nucleoprotein complex is determined. The results of the intracellular editing experiment are shown in Table 7 below.
[0250]
[0251]
[0252]
[0253] StDev = standard deviation; nd = not determined, n = 3
[0254] The data in Table 7 above show that the Cas12a crRNA / nucleoprotein complex is able to target multiple genes in mouse H2.35 cells. AsCas12a or other Cas12a proteins (such as Lachnospiraceae bacteria or Francisella novicida) can be used to target other genes in a similar manner, such as genes described elsewhere herein.
[0255] Example 10. Engineering the Cas12a chRDNA guide molecule to have DNA in the activation region sequence.
[0256] The following example describes engineering the AsCas12a chRDNA guide molecule to include DNA bases in the activation region sequence.
[0257] A. In silico design of Cas12a chRDNA guide
[0258] The 20-nucleotide activation region sequence of the AsCas12a guide (SEQ ID NO: 03) was selected for engineering, and DNA bases were designed to replace RNA at positions 1, 3, 7, 10, 12, 14, 15, and 19 (counting along the guide in the 5' to 3' direction).
[0259] Nine target sequences were selected from the target list shown in Table 7 of Example 9 and engineered to have DNA bases in the activation region sequence, and the target sequences and Cas12a crRNA control sequences were provided to commercial manufacturers for synthesis.
[0260] B. Cell Transfection and Analysis
[0261] Individual Cas12a guide / nucleoprotein complexes for screening were prepared essentially as described in Example 7. The nucleoprotein complexes were transfected into H2.35 cells as described in Example 8, and the genome editing efficiency of the resulting Cas12a guide / nucleoprotein complexes was determined as described in Example 9. The results of the intracellular editing experiments are shown in Table 8 below.
[0262]
[0263]
[0264] StDev = standard deviation; n = 3
[0265] The data presented in Table 8 above show that AsCas12a guides with DNA in the activation region sequence are able to achieve on-target editing rates comparable to all RNA guides (e.g., compare SEQ ID NO: 148 with SEQ ID NO: 149; SEQ ID NO: 153 with SEQ ID NO: 154; SEQ ID NO: 160 with SEQ ID NO: 161). Other guides, such as guides described elsewhere herein, can be engineered to have DNA in the activation region sequence using AsCas12a or other Cas12a proteins (such as Lachnospiraceae bacteria or Francisella novicida) in a similar manner.
[0266] Example 11. Engineering a Cas12a chRDNA guide molecule to have DNA in the guide repeat sequence.
[0267] The following example describes engineering the AsCas12a chRDNA guide molecule to include DNA bases in the target binding sequence.
[0268] A. In silico design of Cas12a chRDNA guide
[0269] A target sequence was selected for engineering in the genes encoding mouse PCSK9 (PCSK9-tgt9), TTR (TTR-tgt5), and ANGPTL3 (ANGPLT3-tgt18). The Cas12a chRDNA guide for each target and the Cas12acrRNA control sequence were provided to a commercial manufacturer for synthesis, and the guide included individual DNA bases at the localization subset in the target binding sequence (SEQ ID NO: 74, SEQ ID NO: 92, SEQ ID NO: 22, and SEQ ID NO: 95-130).
[0270] B. Cell Transfection and Analysis
[0271] Individual Cas12a guide / nucleoprotein complexes for screening were prepared essentially as described in Example 7. The nucleoprotein complexes were transfected into H2.35 cells as described in Example 8, and the genome editing efficiency of the resulting Cas12a guide / nucleoprotein complexes was determined as described in Example 9. The results of the intracellular editing experiments are shown in Table 9 below.
[0272]
[0273]
[0274] StDev = standard deviation; n = 3
[0275] The editing results in Table 9 above show that the Cas12a chRDNA guide molecules including DNA in the spacer can be edited across multiple targets at a rate comparable to crRNA (compare SEQ ID NO: 148 with SEQ ID NO: 103; SEQ ID NO: 152 with SEQ ID NO: 109; SEQ ID NO: 156 with SEQ ID NO: 130). The editing rates of the chRDNA guide designs in Table 3 were normalized relative to the editing rates of the crRNA for each target and used to determine which locations within the target binding sequence of the selected target can be engineered into the DNA in the Cas12a guide.
[0276] Example 12. Cas12a chRDNA guide molecules with multiple DNA bases in the target binding sequence.
[0277] This example describes the design and testing of Cas12a chRDNA guide molecules with multiple DNA bases in the target binding sequence.
[0278] A. In silico design of the Cas12a chRDNA guide
[0279] The 20-nucleotide sequences of three targets (B2M-tgt12, B2M-tgt1, B2M-intron-tgt12) in the gene encoding human B2M, the target (TRAC-tgt12) in the gene encoding human TRAC and the target (DNMT1-tgt1) in the gene encoding human DNA methyltransferase 1 are selected for editing. For each target, 1 to 7 nucleotides of DNA are designed into the target binding sequence of each AsCas12a guide. The design criteria for the positioning of DNA bases include but are not limited to the previous single positioning screening data (see Example 10), the previous consensus on the positioning of tolerant DNA, the distance between the individual DNA bases in the target binding sequence and the mismatch position known in the off-target sequence. The Cas12a chRDNA guide design and the control sequence ("V3'" in Table 10) without DNA in the target binding sequence are provided to commercial manufacturers for synthesis.
[0280] B. Cell Transfection and Analysis
[0281] Individual Cas12a guide / nucleoprotein complexes for screening were prepared essentially as described in Example 7. Cas12a guide / nucleoprotein complexes were transfected into primary T cells as described in Example 8, and the genome editing efficiency of the resulting Cas12a guide / nucleoprotein complexes was determined as described in Example 9. The results of the intracellular editing experiments and the positions of the DNA bases in the target binding sequence of each Cas12a chRDNA guide are shown in Table 10 below.
[0282]
[0283]
[0284] StDev = standard deviation; n = 3
[0285] The editing results in Table 10 above indicate that Cas12a chRDNA guide molecules including multiple DNA bases in the target binding sequence are able to edit across multiple targets at a rate comparable to crRNA (compare SEQ ID NO: 136 with SEQ ID NO: 131; SEQ ID NO: 141 with SEQ ID NO: 139 or SEQ ID NO: 147 with SEQ ID NO: 142).
[0286] Although the present invention has been described in detail with reference to specific examples, it will be apparent to those skilled in the art that various modifications may be made within the scope of the present invention. Therefore, the scope of the present invention should not be limited to the examples described herein, but should be limited by the following claims.
Claims
1. A method for treating a disease or condition characterized by abnormal expression of a gene, the method comprising introducing into a somatic cell of a patient suffering from the disease or condition: (a) a first nucleoprotein complex, comprising a Cas12a protein and a first CRISPR guide molecule, wherein the first CRISPR guide molecule has a targeting region capable of binding to a first target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving the first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; and (b) a donor polynucleotide comprising a coding sequence for a gene target that is aberrantly expressed in an individual suffering from the disease or condition; wherein cleavage by the Cas12a protein causes the coding sequence to be inserted into the genome of the somatic cell, and wherein the introducing is performed by contacting the somatic cell with a lipid nanoparticle comprising the first nucleoprotein complex and the donor polynucleotide, and Wherein the gene target is selected from Table 3.
2. The method of claim 1, wherein in the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide.
3. The method according to claim 1, further comprising introducing a second nucleoprotein complex comprising a Cas12a protein and a second CRISPR guide molecule into the somatic cell, wherein the second CRISPR guide molecule has a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving the second target nucleic acid; Wherein the coding sequence is inserted between the cleavage sites in the first target nucleic acid cleaved by the Cas12a protein and the second target nucleic acid.
4. The method of claim 3, wherein the second CRISPR guide molecule comprises at least one deoxyribonucleotide.
5. The method of claim 1, wherein said inserting the coding sequence into the genome of the somatic cell results in increased expression of the gene in the somatic cell.
6. The method of claim 1, wherein the lipid nanoparticles comprise one or more cationic lipids, wherein the pK of the lipid or a combination of two or more lipids is a Between 6.1 and 6.
7.
7. The method of claim 1, wherein the lipid nanoparticles comprise neutral lipids.
8. The method of claim 1, wherein the lipid nanoparticles comprise a sterol.
9. The method of claim 1, wherein the lipid nanoparticles comprise one or more lipids selected from the group consisting of DSPC, DPPC, POPC, DOPE, SM, PEG-DMA, PEG-DMG, DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE, GL67A-DOPE-DMPE-PEG, 98N12-5, C12-200, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, 7C1, PEG-CerC14, and PEG-CerC20.
10. The method of claim 1, wherein the introduction into a somatic cell is performed ex vivo.
11. The method of claim 1, wherein the introduction into somatic cells is performed by systemic intravenous administration, administration into the portal vein, or by intraocular administration.
12. A therapeutic composition for treating a disease or condition characterized by abnormal expression of a gene, the composition comprising: (a) a first nucleoprotein complex, comprising a Cas12a protein and a first CRISPR guide molecule, wherein the first CRISPR guide molecule has a targeting region capable of binding to a first target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving the first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; and (b) a donor polynucleotide comprising a coding sequence for a gene target that is aberrantly expressed in an individual suffering from the disease or condition; Wherein the first nucleoprotein complex and the donor polynucleotide are present in lipid nanoparticles, and wherein the gene target is selected from Table 3.
13. The composition of claim 12, wherein in the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide.
14. The composition according to claim 12, further comprising a second nucleoprotein complex, comprising a Cas12a protein and a second CRISPR guide molecule, wherein the second CRISPR guide molecule has a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cutting a second target nucleic acid.
15. The composition of claim 12, wherein the second CRISPR guide molecule comprises at least one deoxyribonucleotide.
16. The composition of claim 12, wherein the lipid nanoparticles comprise one or more cationic lipids, wherein the pK of the lipid or a combination of two or more lipids is a Between 6.1 and 6.
7.
17. The composition of claim 12, wherein the lipid nanoparticles comprise neutral lipids.
18. The composition of claim 12, wherein the lipid nanoparticles comprise a sterol.
19. The composition of claim 12, wherein the lipid nanoparticles comprise one or more lipids selected from the group consisting of DSPC, DPPC, POPC, DOPE, SM, PEG-DMA, PEG-DMG, DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE, GL67A-DOPE-DMPE-PEG, 98N12-5, C12-200, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, 7C1, PEG-CerC14, and PEG-CerC20.
20. The composition of claim 12, further comprising a pharmaceutically acceptable carrier.
21. A method for treating a disease or condition characterized by abnormal gene expression using genetically modified differentiated induced pluripotent stem cells (iPSCs), the method comprising (1) Introduce the following into iPSCs: A first nucleoprotein complex, comprising a Cas12a protein and a first CRISPR guide molecule, wherein the first CRISPR guide molecule has a targeting region capable of binding to a first target nucleic acid sequence; as well as An activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; Wherein the cleavage performed by the Cas12a protein causes modification of a gene target selected from Table 4 or Table 5; (2) differentiating the iPSCs into a cell type affected by the disease or condition in an individual suffering from the disease or condition; as well as (3) administering the differentiated iPSCs to a patient affected by the disease or condition.
22. The method of claim 21, wherein in the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide.
23. The method according to claim 21, further comprising introducing a second nucleoprotein complex comprising a Cas12a protein and a second CRISPR guide molecule into the iPSC, wherein the second CRISPR guide molecule has a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving the second target nucleic acid; Wherein the coding sequence is inserted between the cleavage sites in the first target nucleic acid cleaved by the Cas12a protein and the second target nucleic acid.
24. The method of claim 23, wherein the second CRISPR guide molecule comprises at least one deoxyribonucleotide.
25. The method of claim 21, further comprising introducing a donor polynucleotide into the iPSC, the donor polynucleotide comprising a coding sequence for a gene target selected from Table 4.
26. The method of claim 25, wherein the cleavage with the Cas12a protein causes the coding sequence to be inserted into the genome of the iPSC.
27. The method of claim 26, wherein said inserting the coding sequence into the genome of the iPSC results in increased expression of the gene in the iPSC.
28. The method of claim 21, wherein the cleavage performed with the Cas12a protein causes destruction of the coding sequence of the gene target listed in Table 5 in the genome of the iPSC.
29. The method of claim 28, wherein the disruption in the genome of the iPSC causes reduced expression of the gene in the iPSC.
30. The method of claim 21, wherein the iPSCs are generated by reprogramming somatic cells.
31. The method of claim 26, wherein the reprogramming is performed by inducing expression of one or more genes in the somatic cells.
32. The method of claim 26, wherein the reprogramming is performed by inducing gene expression by introducing mRNA into the somatic cell.
33. The method of claim 27, wherein the one or more genes are selected from Oct4, Sox2, Klf4, c-Myc, NANOG, Sox1, Sox3, Sox15, Sox18, Klf1, Klf2, Klf5, NR5A2, c-Myc, l-Myc, n-Myc, Rem2, Tert, LIN28, and Wnt.
34. The method of claim 27, wherein the one or more genes consist of a combination of Oct4, Sox2, Klf4, and c-Myc.
35. The method of claim 27, wherein the one or more genes consist of a combination of Oct4, Sox2, and NANOG.
36. The method of claim 26, wherein the reprogramming further comprises contacting the iPSC with one or more of: a MEK inhibitor, a DNA methyltransferase inhibitor, a histone deacetylase (HDAC) inhibitor, valproic acid, 5'-azacytidine, dexamethasone, suberoylanilide hydroxamic acid (SAHA), vitamin C and trichostatin (TSA), suberoylanilide hydroxamic acid (SAHA (e.g., MK0683, vorinostat) and other hydroxamic acids), BML-210, Depudecin (e.g., (-)-Depudecin), HC toxin, Nullscript (4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxybutyramide), phenylbutyrate (e.g., sodium phenylbutyrate), and valproic acid ((VP A) and other short-chain fatty acids), Scriptaid, Suramin Sodium, Trichostatin A (TSA), APHA Compound 8, Apicidin, Sodium Butyrate, Pivanex, AN-9, Trapoxin B, Chlamydocin, Depsipeptide (also known as FR901228 or FK228), Benzamides (e.g., CI-994 (e.g., N-acetyl pyridamole), dinaline) and MS-27-275), MGCD0103, NVP-LAQ-824, CBHA (m-carboxycinnamic acid dihydroxamic acid), JNJ16241199, Tubacin, A-161906, proxamide, oxamflatin, 3-C1-UCHA (e.g., 6-(3-chlorophenylureido)hexanehydroxamic acid), AOE (2-amino-8-oxo-9,10-epoxydecanoic acid), CHAP31 and CHAP50.
37. The method of claim 21, wherein the iPSCs are differentiated into neurons.
38. The method of claim 33, wherein the iPSCs are differentiated into neurons by incubating the iPSCs in the presence of one or more of: a GSK-3 inhibitor, a TGF-β receptor or a TGF-β inhibitor, an ALK inhibitor, dorsomorphin, Compound E, FGF, EGF, all-trans retinoic acid, Sonic Hedgehog protein, purmorphamine, SAG dihydrochloride, CNTF, and GDNF.
39. The method of claim 33, wherein the differentiation of iPSCs into neurons is assessed by measuring the expression of one or more of Sox1, Pax6, Nestin, HB9, MAP2, Neurofilament, Tuj1, and Olig2 after the differentiation process.
40. The method of claim 33, wherein the differentiation of iPSCs into neurons is assessed by measuring electrical activity of the cells after the differentiation process.
41. The method of claim 21, wherein the iPSCs are differentiated into muscle cells.
42. The method of claim 37, wherein the iPSCs are differentiated into myocytes by incubating the iPSCs in the presence of one or more of a GSK-3 inhibitor and a Wnt-dependent phosphorylation blocker.
43. The method of claim 37, wherein the differentiation of iPSCs into myocytes is assessed by measuring the expression of one or more of TBX5, TNNT2, MYH6, and MYL7 after the differentiation process.
44. A composition for treating a disease or condition characterized by abnormal expression of a gene using genetically modified differentiated induced pluripotent stem cells (iPSCs), the composition comprising iPSCs, the iPSCs comprising: A first nucleoprotein complex, comprising a Cas12a protein and a first CRISPR guide molecule, wherein the first CRISPR guide molecule has a targeting region capable of binding to a first target nucleic acid sequence; as well as An activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; Wherein the cleavage performed by the Cas12a protein causes modification of a gene target selected from Table 4 or Table 5; and The iPSCs are capable of differentiating into a cell type affected by the disease or condition in an individual suffering from the disease or condition.
45. The composition of claim 44, wherein in the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide.
46. The composition of claim 44, further comprising introducing a second nucleoprotein complex comprising a Cas12a protein and a second CRISPR guide molecule into the iPSC, wherein the second CRISPR guide molecule has a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving the second target nucleic acid; Wherein the coding sequence is inserted between the cleavage sites in the first target nucleic acid cleaved by the Cas12a protein and the second target nucleic acid.
47. The composition of claim 45, wherein the second CRISPR guide molecule comprises at least one deoxyribonucleotide.
48. The composition of claim 44, further comprising a donor polynucleotide comprising a coding sequence for a gene target selected from Table 4.
49. A composition according to claim 48, wherein the cleavage performed with the Cas12a protein causes the coding sequence to be inserted into the genome of the iPSC.
50. The composition of claim 49, wherein the inserting of the coding sequence into the genome of the iPSC results in increased expression of the gene in the iPSC.
51. The composition of claim 44, wherein the cleavage performed with the Cas12a protein causes destruction of the coding sequence of the gene target listed in Table 5 in the genome of the iPSC.
52. The composition of claim 51, wherein the disruption in the genome of the iPSC causes reduced expression of the gene in the iPSC.
53. The composition of claim 44, wherein the iPSCs are generated by reprogramming somatic cells.
54. The composition of claim 53, wherein the reprogramming is performed by inducing expression of one or more genes in the somatic cells.
55. The composition of claim 54, wherein the reprogramming is performed by inducing gene expression by introducing mRNA into the somatic cell.
56. The composition of claim 54, wherein the one or more genes are selected from Oct4, Sox2, Klf4, c-Myc, NANOG, Sox1, Sox3, Sox15, Sox18, Klf1, Klf2, Klf5, NR5A2, c-Myc, l-Myc, n-Myc, Rem2, Tert, LIN28, and Wnt.
57. The composition of claim 54, wherein the one or more genes consist of a combination of Oct4, Sox2, Klf4, and c-Myc.
58. The composition of claim 54, wherein the one or more genes consist of a combination of Oct4, Sox2, and NANOG.
59. The composition of claim 53, wherein the reprogramming further comprises contacting the iPSC with one or more of: a MEK inhibitor, a DNA methyltransferase inhibitor, a histone deacetylase (HDAC) inhibitor, valproic acid, 5'-azacytidine, dexamethasone, suberoylanilide hydroxamic acid (SAHA), vitamin C and trichostatin (TSA), suberoylanilide hydroxamic acid (SAHA (e.g., MK0683, vorinostat) and other hydroxamic acids), BML-210, Depudecin (e.g., (-)-Depudecin), HC toxin, Nullscript (4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxybutyramide), phenylbutyrate (e.g., sodium phenylbutyrate), and valproic acid ((VP A) and other short-chain fatty acids), Scritex, suramin sodium, trichostatin A (TSA), APHA compound 8, aphidicolin, sodium butyrate, pivaloyloxymethylbutyrate (Pivanex, AN-9), Triproxin B, Chlamydocin, depsipeptide (also known as FR901228 or FK228), benzamides (e.g., CI-994 (e.g., N-acetyl pyridamole), and MS-27-275 ), MGCD0103, NVP-LAQ-824, CBHA (m-carboxycinnamic acid dihydroxamic acid), JNJ16241199, tubasin, A-161906, proxamide, oxamflatin, 3-C1-UCHA (e.g., 6-(3-chlorophenylureido)hexanehydroxamic acid), AOE (2-amino-8-oxo-9,10-epoxydecanoic acid), CHAP31 and CHAP50.
60. The composition of claim 44, wherein the iPSCs are differentiated into neurons.
61. The composition of claim 60, wherein the iPSCs are differentiated into neurons by incubating the iPSCs in the presence of one or more of: a GSK-3 inhibitor, a TGF-β receptor or a TGF-β inhibitor, an ALK inhibitor, doxorubicin, Compound E, FGF, EGF, all-trans retinoic acid, sonic hedgehog, purmorphamine, SAG dihydrochloride, CNTF, and GDNF.
62. The composition of claim 60, wherein the differentiation of iPSCs into neurons is assessed by measuring the expression of one or more of Sox1, Pax6, Nestin, HB9, MAP2, Neurofilament, Tuj1, and Olig2 after the differentiation process.
63. The composition of claim 60, wherein the differentiation of iPSCs into neurons is assessed by measuring electrical activity of the cells after the differentiation process.
64. The composition of claim 44, wherein the iPSCs are differentiated into muscle cells.
65. The composition of claim 64, wherein the iPSCs are differentiated into myocytes by incubating the iPSCs in the presence of one or more of a GSK-3 inhibitor and a Wnt-dependent phosphorylation blocker.
66. The composition of claim 64, wherein the differentiation of iPSCs into muscle cells is assessed by measuring the expression of one or more of TBX5, TNNT2, MYH6, and MYL7 after the differentiation process.
67. The composition of claim 44, further comprising a pharmaceutically acceptable carrier.
68. A method for preparing a genetically modified differentiated induced pluripotent stem cell (iPSC) for treating a disease or condition characterized by abnormal gene expression, the method comprising (1) Introduce the following into iPSCs: A first nucleoprotein complex, comprising a Cas12a protein and a first CRISPR guide molecule, wherein the first CRISPR guide molecule has a targeting region capable of binding to a first target nucleic acid sequence; as well as An activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; Wherein the cleavage performed by the Cas12a protein causes modification of a gene target selected from Table 4 or Table 5; (2) differentiating the iPSCs into a cell type affected by the disease or condition in an individual suffering from the disease or condition; as well as (3) administering the differentiated iPSCs to a patient affected by the disease or condition.
69. The method of claim 68, wherein in the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide.
70. The method of claim 68, further comprising introducing into the iPSC a second nucleoprotein complex comprising a Cas12a protein and a second CRISPR guide molecule, wherein the second CRISPR guide molecule has a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving the second target nucleic acid; Wherein the coding sequence is inserted between the cleavage sites in the first target nucleic acid cleaved by the Cas12a protein and the second target nucleic acid.
71. The method of claim 70, wherein the second CRISPR guide molecule comprises at least one deoxyribonucleotide.
72. The method of claim 68, further comprising introducing a donor polynucleotide into the iPSC, the donor polynucleotide comprising a coding sequence for a gene target selected from Table 4.
73. The method of claim 72, wherein the cleavage with the Cas12a protein causes the insertion of the coding sequence into the genome of the iPSC.
74. The method of claim 73, wherein said inserting said coding sequence into the genome of said iPSC results in increased expression of said gene in said iPSC.
75. The method of claim 68, wherein the cleavage performed with the Cas12a protein causes destruction of the coding sequence of the gene target listed in Table 5 in the genome of the iPSC.
76. The method of claim 75, wherein the disruption in the genome of the iPSC causes reduced expression of the gene in the iPSC.
77. The method of claim 68, wherein the iPSCs are generated by reprogramming somatic cells.
78. The method of claim 77, wherein the reprogramming is performed by inducing expression of one or more genes in the somatic cells.
79. The method of claim 77, wherein the reprogramming is performed by inducing gene expression by introducing mRNA into the somatic cell.
80. The method of claim 78, wherein the one or more genes are selected from Oct4, Sox2, Klf4, c-Myc, NANOG, Sox1, Sox3, Sox15, Sox18, Klf1, Klf2, Klf5, NR5A2, c-Myc, l-Myc, n-Myc, Rem2, Tert, LIN28, and Wnt.
81. The method of claim 78, wherein the one or more genes consist of a combination of Oct4, Sox2, Klf4, and c-Myc.
82. The method of claim 78, wherein the one or more genes consist of a combination of Oct4, Sox2, and NANOG.
83. The method of claim 77, wherein the reprogramming further comprises contacting the iPSC with one or more of: a MEK inhibitor, a DNA methyltransferase inhibitor, a histone deacetylase (HDAC) inhibitor, valproic acid, 5'-azacytidine, dexamethasone, suberoylanilide hydroxamic acid (SAHA), vitamin C and trichostatin (TSA), suberoylanilide hydroxamic acid (SAHA (e.g., MK0683, vorinostat) and other hydroxamic acids), BML-210, Depudecin (e.g., (-)-Depudecin), HC toxin, Nullscript (4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxybutyramide), phenylbutyrate (e.g., sodium phenylbutyrate), and valproic acid ((VP A) and other short-chain fatty acids), Scritex, suramin sodium, trichostatin A (TSA), APHA compound 8, aphidicolin, sodium butyrate, pivaloyloxymethylbutyrate (Pivanex, AN-9), Trapoxin B ( B), Chlamydocin, depsipeptide (also known as FR901228 or FK228), benzamides (e.g., CI-994 (e.g., N-acetyldinaline) and MS-27-275), MGCD0103, NVP-LAQ-824, CBHA (m-carboxycinnamic acid dihydroxamic acid), JNJ16241199, tobacin, A-161906, proxamide, oxamflatin, 3-C1-UCHA (e.g., 6-(3-chlorophenylureido)hexanehydroxamic acid), AOE (2-amino-8-oxo-9,10-epoxydecanoic acid), CHAP31 and CHAP50.
84. The method of claim 68, wherein the iPSCs are differentiated into neurons.
85. The method of claim 84, wherein the iPSCs are differentiated into neurons by incubating the iPSCs in the presence of one or more of: a GSK-3 inhibitor, a TGF-β receptor or a TGF-β inhibitor, an ALK inhibitor, doxorubicin, Compound E, FGF, EGF, all-trans retinoic acid, sonic hedgehog, purmorphamine, SAG dihydrochloride, CNTF, and GDNF.
86. The method of claim 85, wherein the differentiation of iPSCs into neurons is assessed by measuring the expression of one or more of Sox1, Pax6, Nestin, HB9, MAP2, Neurofilament, Tuj1, and Olig2 after the differentiation process.
87. The method of claim 85, wherein the differentiation of iPSCs into neurons is assessed by measuring electrical activity of the cells after the differentiation process.
88. The method of claim 68, wherein the iPSCs are differentiated into muscle cells.
89. The method of claim 88, wherein the iPSCs are differentiated into myocytes by incubating the iPSCs in the presence of one or more of a GSK-3 inhibitor and a Wnt-dependent phosphorylation blocker.
90. The method of claim 88, wherein the differentiation of iPSCs into myocytes is assessed by measuring the expression of one or more of TBX5, TNNT2, MYH6, and MYL7 after the differentiation process.
91. A method for preparing a transgenic animal for xenotransplantation, the method comprising: (1) Introducing the following into the cells of an animal: A first nucleoprotein complex, comprising a Cas12a protein and a first CRISPR guide molecule, wherein the first CRISPR guide molecule has a targeting region capable of binding to a first target nucleic acid sequence; as well as An activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; Wherein the cleavage performed by the Cas12a protein causes modification of a gene target selected from Table 6; (2) Introducing the cells into a foster female animal.
92. The method of claim 91, wherein the cell of the animal is an oocyte, an egg, or a fertilized egg.
93. The method according to claim 91, wherein the cell of the animal is a somatic cell, and the method further comprises, after step (1), transferring the nucleus of the cell into an enucleated egg or a fertilized egg.
94. The method of claim 91, wherein the animal is a pig.
95. The method of claim 91, wherein in the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide.
96. The method of claim 91, further comprising introducing into the iPSC a second nucleoprotein complex comprising a Cas12a protein and a second CRISPR guide molecule, wherein the second CRISPR guide molecule has a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving the second target nucleic acid; Wherein the coding sequence is inserted between the cleavage sites in the first target nucleic acid cleaved by the Cas12a protein and the second target nucleic acid.
97. The method of claim 96, wherein the second CRISPR guide molecule comprises at least one deoxyribonucleotide.
98. The method of claim 91, further comprising introducing a donor polynucleotide into the cell, wherein the donor polynucleotide comprises a coding sequence for a gene target selected from the group consisting of: A20, HO-1, FAT-1, TNF-α receptor, CD39, hirudin, TFPI, EPCR, TBM, CD46, DAF (CD55), CD59, CR1, CTLA4, CD47, and one or more class I HLA.
99. The method of claim 98, wherein the cleavage performed with the Cas12a protein causes the coding sequence to be inserted into the genome of the cell.
100. The method of claim 99, wherein said inserting said coding sequence into the genome of said cell results in increased expression of said gene in said cell.
101. The method of claim 91, wherein the cleavage with the Cas12a protein causes destruction of a coding sequence of a gene target selected from the group consisting of GGTA1, b4GalNT2, CMAH, GT (α(1,3)-galactosyltransferase), GHR, and one or more class I SLAs in the genome of the cell.
102. The method of claim 101, wherein the disruption in the genome of the cell causes reduced expression of the gene in the cell.
103. A composition for preparing a transgenic animal for xenotransplantation, the composition comprising an animal cell, the animal cell comprising: A first nucleoprotein complex, comprising a Cas12a protein and a first CRISPR guide molecule, wherein the first CRISPR guide molecule has a targeting region capable of binding to a first target nucleic acid sequence; as well as An activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving a first target nucleic acid, wherein the first CRISPR guide molecule comprises at least one deoxyribonucleotide; Wherein the cleavage performed by the Cas12a protein causes modification of a gene target selected from Table 6.
104. The composition of claim 103, wherein the animal's cell is an oocyte, an egg or a fertilized egg.
105. The composition of claim 103, wherein the cell of the animal is an egg or a fertilized egg produced by transferring the nucleus of a somatic cell into an enucleated egg or a fertilized egg.
106. The composition of claim 103, wherein the animal is a pig.
107. The composition of claim 103, wherein in the CRISPR guide molecule, the activation region, the targeting region, or both comprise at least one deoxyribonucleotide.
108. The composition of claim 103, further comprising introducing a second nucleoprotein complex comprising a Cas12a protein and a second CRISPR guide molecule into the iPSC, wherein the second CRISPR guide molecule has a targeting region capable of binding to a second target nucleic acid sequence; and an activation region capable of forming a nucleoprotein complex with the Cas12a protein, and the Cas12a protein is capable of cleaving the second target nucleic acid; Wherein the coding sequence is inserted between the cleavage sites in the first target nucleic acid cleaved by the Cas12a protein and the second target nucleic acid.
109. The composition of claim 108, wherein the second CRISPR guide molecule comprises at least one deoxyribonucleotide.
110. The composition of claim 103, further comprising a donor polynucleotide comprising a coding sequence for a gene target selected from the group consisting of: A20, HO-1, FAT-1, TNF-α receptor, CD39, hirudin, TFPI, EPCR, TBM, CD46, DAF (CD55), CD59, CR1, CTLA4, CD47, and one or more class I HLA.
111. The composition of claim 110, wherein the cleavage performed with the Cas12a protein causes the coding sequence to be inserted into the genome of the cell.
112. The composition of claim 111, wherein said inserting said coding sequence into the genome of said cell results in increased expression of said gene in said cell.
113. The composition of claim 103, wherein the cleavage with the Cas12a protein causes destruction of a coding sequence of a gene target selected from the group consisting of GGTA1, b4GalNT2, CMAH, GT (α(1,3)-galactosyltransferase), GHR, and one or more class I SLAs in the genome of the cell.
114. The composition of claim 113, wherein the disruption in the genome of the cell causes reduced expression of the gene in the cell.
